CONFIDENTIAL  
 TMF-17008580  
 218806  
1  CLINICAL STUDY PROTO COL  
Primary Study Intervention(s)  VH4524184  
Other Study Intervention(s)  N/A 
Study Identifier  [ADDRESS_371604] Number   2023 -507173 -18-00 
Approval Date  29 Sep 2023   
Title  A Randomized, Double -Blind (Sponsor Unblinded), 
Placebo -Controlled, Study to Investigate the Antiviral 
Effect, Safety, Tolerability and Pharmacokinetics of 
VH4524184 in HIV -1 Infected Treatment Naïve Adults   
Compound Number/Name  [CONTACT_23983]4524184 (also known as VH4524184)  
Brief Title  VH4524184 Proof -of-Concept in Treatment -Naïve Adults 
Living with HIV -1 
Sponsor  ViiV Healthcare group of companies  
Sponsor Name [CONTACT_29560] 
(excluding US):  
ViiV Healthcare [LOCATION_006] Limited  
[ADDRESS_371605]  
Middlesex, TW8 9GS, [LOCATION_006]  
US IND Sponsor Name [CONTACT_29560]:  
ViiV Healthcare Company  
[ADDRESS_371606] information 
document  
©2023 ViiV Healthcare and the [COMPANY_004] group of companies.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
2 Protocol Investigator Agreement  
I agree:  
• To conduct the study in compliance with this protocol, any future protocol 
amendments, with the terms of the clinical trial agreement and with any other study 
conduct procedures and/or study conduct documents provided by [CONTACT_103673].  
• To assume responsibility for the proper conduct of the study at this site.  
• That I am aware of and will comply with GCP and all applicable regu latory 
requirements.  
• That I will comply with the terms of the site agreement.  
• To comply with local bio -safety legislation.  
• To ensure that all persons assisting me with the study are adequately informed about 
the ViiV Healthcare study intervention and othe r study -related duties and functions as 
described in the protocol.  
• To supervise any individual or party to whom I have delegated study -related duties 
and functions conducted at the study site.  
• To ensure that any individual or party to whom I have delegated  study -related duties 
and functions conducted at the study site are qualified to perform those study -related 
duties and functions.  
• To acquire the reference ranges for laboratory tests performed locally and, if required 
by [CONTACT_427], obtain the laboratory’s current certification or Quality Assurance 
procedure manual.  
• To ensure that no clinical samples (including serum samples) are retained on -site or 
elsewhere without the approval of ViiV Healthcare and the express  physical and/or 
digital  informed consent of the participant .  
• To perform no biological assays on the clinical samples other than those described in 
the protocol or its amendment(s). To co -operate with representative(s) of ViiV 
Healthcare in the monitoring and data management pr ocesses of the study with 
respect to data entry and resolution of queries about the data.  
• To have control of all essential documents and records generated under my 
responsibility before, during, and after the study.  
• That I have been informed that certain r egulatory authorities require the sponsor to 
obtain and supply, as necessary, details about the investigator(s)’ ownership interest 
in the sponsor or the study intervention(s), and more generally about their financial 
ties with the sponsor. ViiV Healthcare  will use and disclose the information solely for 
the purpose of complying with regulatory requirements.  
Hence, I:  
CONFIDENTIAL  
 TMF-17008580  
 218806  
3 • Agree to supply  ViiV Healthcare with any necessary information regarding ownership 
interest and financial ties (including those of my spouse and dependent children).  
• Agree to promptly update this information if any relevant changes occur during the 
study and for 1 year following completion of the study.  
• Agree that ViiV Healthcare may disclose any information about such ownership 
interests and f inancial ties to regulatory authorities.  
• Agree to provide ViiV Healthcare with an updated Curriculum Vitae and all other 
documents required by [CONTACT_227236].  
CONFIDENTIAL  
 TMF-[ADDRESS_371607] number  2023 -507173 -18-00 
Approval date  29 Sep 2023  
  
Title  A Randomized, Double -Blind (Sponsor Unblinded), 
Placebo -Controlled, Study to Investigate the 
Antiviral Effect, Safety, Tolerability and 
Pharmacokinetics of VH4524184 in HIV -1 Infected 
Treatment Naïve Adults  
Investigator name   
  
[CONTACT_103744]  
(DD Month YYYY)   
  
 
  
CONFIDENTIAL  
 TMF-17008580  
 218806  
5 TABLE OF CONTENTS  
PAGE  
1. PROTOCOL SUMMARY  ................................ ................................ ........................  19 
1.1. Synopsis  ................................ ................................ ................................ ..... 19 
1.2. Schema  ................................ ................................ ................................ ...... 23 
1.3. Schedule of  activities (SoA)  ................................ ................................ ........  24 
1.3.1.  Screening and Monotherapy Period  ................................ .............  25 
1.3.2.  Open Label Follow -up Period ................................ .......................  31 
2. INTRODUCTION  ................................ ................................ ................................ .... 33 
2.1. Study r ationale  ................................ ................................ ............................  33 
2.2. Background  ................................ ................................ ................................  33 
2.2.1.  Unmet Medical Need  ................................ ................................ ... 33 
2.3. Benefit/risk assessment  ................................ ................................ ..............  35 
2.3.1.  Risk assessment  ................................ ................................ ..........  36 
2.3.2.  Benefit assessment  ................................ ................................ ..... 41 
2.3.3. Overall benefit -risk conclusion  ................................ .....................  41 
3. OBJECTIVES, ENDPOINT S AND ESTIMANDS  ................................ ....................  42 
3.1. Primary estimand  ................................ ................................ ........................  43 
3.1.1.  Antiviral activity  ................................ ................................ ............  43 
3.2. Key secondary estimand(s)  ................................ ................................ ........  43 
3.2.1.  Safety and tolerability ................................ ................................ ... 43 
3.2.2.  Pharmacokinetic profile  ................................ ................................  45 
4. STUDY DESIGN  ................................ ................................ ................................ .... 45 
4.1. Overall design  ................................ ................................ .............................  45 
4.2. Scientific rationale for study design  ................................ .............................  47 
4.2.1.  Participant input into design  ................................ .........................  48 
4.3. Justification for dose  ................................ ................................ ...................  48 
4.4. End-of-study definition  ................................ ................................ ................  49 
5. STUDY POPULATION  ................................ ................................ ...........................  49 
5.1. Inclusion criteria  ................................ ................................ ..........................  49 
5.2. Exclusion criteria  ................................ ................................ .........................  51 
5.2.1.  Medical Conditions  ................................ ................................ ...... 51 
5.2.2.  Prior/Concomitant Therapy  ................................ ..........................  53 
5.2.3.  Prior/Concurrent Clinical Study Experience  ................................ . 53 
5.2.4.  Diagnostic Assessments  ................................ ..............................  54 
5.2.5.  Other Exclusion Criteria  ................................ ...............................  55 
5.3. Lifestyle considerations  ................................ ................................ ...............  55 
5.3.1.   and dietary restrictions  ................................ ......................  55 
5.3.2.  Alcohol and tobacco  ................................ ................................ .... 55 
5.3.3.  Activity  ................................ ................................ .........................  56 
5.3.4.  Other  restrictions  ................................ ................................ .........  56 
5.4. Screen failures  ................................ ................................ ............................  56 
5.5. Criteria for temporarily delaying 
enrollment/randomization/administration of study intervention  ....................  56 
6. STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY  ..............................  57 
6.1 Study intervention(s) administered  ................................ ..............................  57 
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
6 6.2 Preparation, handling, storage, and accountability  ................................ ...... 59 
6.3 Assignment to study intervention  ................................ ................................  59 
6.4 Blinding, masking  ................................ ................................ ........................  59 
6.4.1  Randomization and treatment assignment  ................................ ... 60 
6.4.2  Central Laboratory  ................................ ................................ ....... 60 
6.4.3  Emergency unblinding  ................................ ................................ . 60 
6.5 Study intervention compliance  ................................ ................................ .... 61 
6.6 Dose modification  ................................ ................................ .......................  61 
6.7 Continued  access to study intervention after the end of the study  ...............  61 
6.8 Treatment of overdose  ................................ ................................ ................  62 
6.9 Prior and concomitant therapy  ................................ ................................ .... 62 
6.9.1  Permitted Medications  ................................ ................................ . 63 
6.9.2  Prohibited Medications  ................................ ................................ . 63 
7 DISCONTINUATION OF S TUDY INTERVENTION AN D PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ..... 64 
7.1 Discontinuation of study intervention  ................................ ...........................  64 
7.1.1  Capturing reason for discontinuation in the eCRF  ........................  65 
7.1.2  Liver chemistry stoppi[INVESTIGATOR_3418]  ................................ ...................  66 
7.1.3  QTc Stoppi[INVESTIGATOR_3418]  ................................ ................................ ... 66 
7.1.4  Pregnancy  ................................ ................................ ...................  67 
7.1.5  Suicid al ideation and behavior  ................................ .....................  67 
7.1.6  Hypersensitivity reactions Stoppi[INVESTIGATOR_2121]  ................................ . 67 
7.1.7  Temporary discontinuation  ................................ ...........................  67 
7.1.8  Rechallenge  ................................ ................................ .................  67 
7.2 Partic ipant discontinuation/withdrawal from the study  ................................ . [ADDRESS_371608] to follow -up................................ ................................ ..........................  69 
8 STUDY ASSESSMENTS AN D PROCEDURES  ................................ .....................  70 
8.1 Administrative and baseline procedures  ................................ .....................  71 
8.1.1  Collection of demographic data  ................................ ....................  71 
8.1.2  Medical/vaccination history  ................................ ..........................  71 
8.2 Efficacy assessments  ................................ ................................ .................  71 
8.2.1 Quantitative HIV -1 RNA  ................................ ...............................  71 
8.2.2  Lymphocyte Subsets by [CONTACT_46110]  ................................ ..... 71 
8.3 Safety assessments  ................................ ................................ ....................  72 
8.3.1  Physical examination/history directed physical examination .........  72 
8.3.2  Vital signs  ................................ ................................ ....................  72 
8.3.3  Electrocardiograms  ................................ ................................ ...... 72 
8.3.4  Clinical safety laboratory tests  ................................ .....................  73 
8.3.5  Pregnancy testing for participants of childbearing potential  ..........  73 
8.3.6  Suicidal ideation and behavior risk monitoring  .............................  74 
8.3.7  Study pausing rules  ................................ ................................ ..... 75 
8.4 Adverse Events (AEs) serious adverse events (SAEs), and other 
safety reporting  ................................ ................................ ...........................  75 
8.4.1  Time period and frequency for collecting AEs and SAEs  .............  76 
8.4.2  Method  of detecting AEs and SAEs  ................................ .............  76 
8.4.3  Follow -up of AEs and SAEs  ................................ .........................  76 
8.4.4  Regulatory reporting requirements for SAEs  ................................  76 
8.4.5  Pregnancy reporting  ................................ ................................ .... 77 
8.4.6  Cardiovascular events and death events  ................................ ..... 78 
CONFIDENTIAL  
 TMF-17008580  
 218806  
7 8.4.7  Disease -related events and/or disease -related outcomes 
not qualifying as AEs or SAEs  ................................ .....................  [ADDRESS_371609]  ................................ ................................ ............  79 
8.5 Pharmacokinetics  ................................ ................................ .......................  79 
8.6 Pharmacodynamics  ................................ ................................ ....................  81 
8.7 Gene tics ................................ ................................ ................................ ..... 81 
8.8 Biomarkers  ................................ ................................ ................................ . 81 
8.9 Immunogenicity assessments  ................................ ................................ ..... 81 
8.10  Health economics or medical resource utilization and health 
economics  ................................ ................................ ................................ .. 81 
9 STATISTICAL CONSIDER ATIONS  ................................ ................................ ........  82 
9.1 Statistical hypotheses  ................................ ................................ .................  82 
9.2 Analysis sets  ................................ ................................ ...............................  82 
9.3 Statistical analyses  ................................ ................................ .....................  83 
9.3.1  General considerations/definitions  ................................ ...............  83 
9.3.2  Primary endpoint/estimand analysis  ................................ .............  83 
9.3.3  Secondary endpoints/estimands analyses  ................................ ... 84 
9.3.4  Exploratory endpoints/estimands analysis  ................................ ... 85 
9.4 Interim analysis  ................................ ................................ ...........................  86 
9.5 Sample size determination  ................................ ................................ ..........  86 
9.5.1  Sample size considerations  ................................ .........................  86 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS  ................................ ................................ ...............................  88 
10.1  Appendix 1: Regulatory, ethical, and study oversight considerations  ..........  88 
10.1.1  Regulatory and ethical considerations  ................................ .........  88 
10.1.2  Financial disclosure  ................................ ................................ ..... 88 
10.1.3  Informed consent process  ................................ ............................  89 
10.1.4  Recruitment strategy  ................................ ................................ .... 89 
10.1.5  Data protection  ................................ ................................ ............  89 
10.1.6  Committee structure  ................................ ................................ .... 90 
10.1.7  Dissemination of Clinical Study Data  ................................ ...........  91 
10.1.8  Data quality assurance  ................................ ................................  91 
10.1.9  Source documents  ................................ ................................ ....... 92 
10.1.10  Study and site start and closure  ................................ ...................  92 
10.1.11  Publication policy  ................................ ................................ .........  93 
10.2 Appendix 2: Clinical laboratory tests  ................................ ...........................  94 
10.3  Appendix 3: AEs and SAEs: Definitions and procedures for 
recording, evaluating, f ollow -up, and reporting  ................................ ............  97 
10.3.1  Definition of AE  ................................ ................................ ............  97 
10.3.2  Definition of SAE  ................................ ................................ ..........  98 
10.3.3 Unsolicited AE  ................................ ................................ .............  99 
10.3.4  Definition of CV events  ................................ ..............................  100 
10.3.5  Definition of TEAE  ................................ ................................ ..... 100 
10.3.6  Recording assessment and follow -up of AEs, SAEs and 
pregnancies  ................................ ................................ ...............  100 
10.3.7  Timeframes for Reporting SAEs, PSRAEs, Pregnancy, and 
Liver Events  ................................ ................................ ...............  104 
10.4  Appendix 4: Contraceptive and barrier guidance  ................................ ....... 106 
CONFIDENTIAL  
 TMF-17008580  
 218806  
8 10.4.1  Definitions  ................................ ................................ ..................  106 
10.4.2  Contraception guidance  ................................ .............................  107 
10.5  Appendix 5: Liver safety: suggested actions and follow -up 
assessments  ................................ ................................ .............................  108 
10.6  Appendix 6: Division of AIDS Table for Grad ing the Severity of Adult 
and Pediatric Adverse Events, Corrected version 2.1, July 2017  ..............  111 
10.6.1  Estimating Severity Grade for Parameters Not  Identified in 
the Grading Table ................................ ................................ ...... 111 
10.6.2  QTc prolongation using the Fridericia formula  ............................  111 
10.7  Appendix 7 : CDC Classification for HIV -[ADDRESS_371610] OF TABLES  
PAGE  
Table 1  Screening and Monotherapy Period Schedule of Activities  .....................  25 
Table 2  Open Label Follow -up Period Schedule of Activities  ..............................  31 
Table 3  Objectives and Endpoints  ................................ ................................ ....... 42 
Table 4  Study Intervention(s) Administered ................................ .........................  57 
Table 5  Study Arm(s)  ................................ ................................ ..........................  [ADDRESS_371611] OF ABBREVIATION S AND DEFINITIONS OF  TERMS  
Abbreviation  Definition  
%CVb  Percentage between -participant coefficient of variation  
ADR  Adverse Drug Reaction  
AE Adverse event  
AIDS  Acquired immunodeficiency syndrome  
AIH  Autoimmune Hepatitis  
ALT  Alanine aminotransferase  
Anti-HBc Antibody to Hepatitis B core antigen  / Hepatitis B core antibody  
Anti-HBs Antibody to  Hepatitis B surface antigen  
ART  Anti-retroviral therapy  
ARV  Antiretroviral  
AST  Aspartate aminotransferase  
AUC(0 -∞) Area under the curve zero to infinity  
BLQ  Below the limit of quantification  
BMI  Body Mass Index  
BUN  Blood urea nitrogen  
CA Competent authority  
CDC  Centers for Disease Control and Prevention  
CFR  Code of Federal Regulation  
CIOMS  Council for International Organizations of Medical Sciences  
CKD -EPI [INVESTIGATOR_82351] - Improved Prediction Equations  
Cmax Maximum observed plasma concentration  
CNS  Central nervous system  
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
11 Abbreviation  Definition  
CONSORT  Consolidated Standards of Reporting Trials  
COVID -19 Coronavirus disease 2019 or Coronavirus  
CPK  Creatine phosphokinase  
CPK  Creatine phosphokinase  
CPMS  Clinical Pharmacology Modeling and Simulation  
CRF/eCRF  Case report form/electronic case repo rt form  
CSR  Clinical study report  
CSSRS  Columbia Suicide Severity Rating Scale  
CV Cardiovascular  
DAIDS  Division of AIDS  
DDI Drug -drug interaction  
DILI  Drug induced liver injury  
DNA  Deoxyribonucleic acid  
DRE  Disease -related event  
EC90  Concentration of drug required for 90% inhibition of the viral 
replication  
ECG  Electrocardiogram  
ED Early discontinuation  
EMA  European Medicines Agency  
EOS End-of-study  
FAS Full analysis set  
FDA  Food and Drug Administration, [LOCATION_002] of America  
FSFV  First participant first visit  
CCI
CONFIDENTIAL  
 TMF-[ADDRESS_371612]-time in human  
GCP  Good clinical practices  
GGT  Gamma glutamyl transferase  
GLDH  Glutamate dehydrogenase  
[COMPANY_004]  GlaxoSmithKline  
H Hour  
HbcAb  Hepatitis B core antibody  / Antibody to Hepatitis B core antigen  
HbsAg  Hepatitis B surface antigen  
HBV  Hepatitis B virus  
HBV DNA  Hepatitis B virus deoxyribonucleic acid  
hCG  Human chorionic gonadotropin  
HCV  Hepatitis C virus  
HCVAb  Hepatitic C virus antibody  
HDL  high-density lipoprotein  
HIPAA  Health Insurance Portability and Accountability Act  
HIV Human immunodeficiency virus  
HIV-1 RNA  human immunodeficiency virus type 1 ribonucleic acid  
HRT  Hormonal replacement therapy  
IB Investigator’s brochure  
ICF Informed consent form  
ICH International Council on Harmonization  
ICSR  Individual case safety reports  
IDSL  Integrated data standards library  
C O N FI D E N TI A L  
 T M F -[ADDRESS_371613] le vel  C CI 
CONFIDENTIAL  
 TMF-17008580  
 218806  
14 Abbreviation  Definition  
NQ Non-quantifiable  
PCR  Polymerase chain reaction  
PD Pharmacodynamic  
PI [INVESTIGATOR_303772]-exposure prophylaxis  
PSRAE  Possible Suicidality -Related AE  
PT Prothrombin time  
PTT Partial thromboplastin time  
PWH  Persons with HIV  
QTc Corrected QT interval  
QTcF  QT Interval corrected for heart rate according to Fridericia’s 
formula  
QTL  Quality tolerance limit  
RBCs  Red blood cells  
RNA  Ribonucleic acid  
RPR  Rapid plasma regain  
CCI
CONFIDENTIAL  
 TMF-[ADDRESS_371614]  Upper limit of normal  
US [LOCATION_002]  
VH ViiV Healthcare  
VLD  Viral load decline  
VSLC  ViiV Healthcare’s  Safety and Labelling Committee  
WBC  White blood cell  
CONFIDENTIAL  
 TMF-17008580  
 218806  
16 Abbreviation  Definition  
WT Wild type  
 
Term  Definition  
Blinding:  A procedure in which [ADDRESS_371615] of the 
study, and only when the data are cleaned to an acceptable 
level of quality will appropriate personnel be unblinded or 
when required in case of a SA E. 
Certified copy  A copy (irrespective of the type of media used) of the 
original record that has been verified (i.e. , by a dated 
signature [INVESTIGATOR_4388] [CONTACT_97214] a validated process) to 
have the same information, including data that describe 
the contex t, content, and structure, as the original.  
Eligible  Qualified for enrollment into the study based upon strict 
adherence to inclusion/exclusion criteria.  
Evaluable  Evaluable participants are defined as those who have PK 
concentration data to allow estima tion of the maximum 
change from baseline (Day 1) in plasma HIV -1 
ribonucleic acid (RNA) through Day [ADDRESS_371616]  An IMP is a pharmaceutical form of an active substance 
or placebo being tested or used as a reference in a clinical 
study, including products already with a marketing 
authorization but used or assembled (formulated or 
packaged) in a way different from the aut horized form, or 
when used for an unauthorized indication, or when used to 
gain further information about the authorized form. 
Medicinal products with a marketing authorization are 
IMPs when they are to be used as the test substance, 
reference substance, o r comparator in a clinical study, 
provided the requirement(s) in the definition is/are met.  
Investigator  A person responsible for the conduct of the clinical study 
at a study site. If a study is conducted by a team of 
individuals at a study site, the inve stigator is the 
CONFIDENTIAL  
 TMF-17008580  
 218806  
17 Term  Definition  
responsible leader of the team and may be called the 
principal investigator.   
The investigator can delegate study -related duties and 
functions conducted at the study site to qualified 
individual or party to perform those study -related dutie s 
and functions  
Participant number  A unique identification number is assigned to each 
participant who consents to participate in the study.  
Participant  Term used throughout the protocol to denote an individual 
who has been contact[CONTACT_303805] a recipi[INVESTIGATOR_175024] 
(vaccine(s)/product(s)/control).  
Synonym: subject  
Randomization  Process of random attribution of intervention to 
participants to reduce selection bias.  
Remote visit  This term refers to the visit conducted in the place other 
than the study site.  
Source data  All information in original records and certified copi[INVESTIGATOR_163503], observations, or other 
activities in a clinical study necessary for the 
reconstruction and evaluation of the study. Source data are 
contained in source documents (original records or 
certified copi[INVESTIGATOR_014]).  
Study intervention  Term used throughout the clinical study to denote a set of 
investigational product(s) or marketed product(s)  or 
placebo intended to be administered to a participant.  
Note: “Study intervention” and “study treatment” are used 
interchangeably unless otherwise specified.  
Study completion date  The date on which the last participant in a clinical study 
was examined o r received an  intervention/treatment  to 
collect final data for the  primary outcome 
measures,  secondary outcome measures, and  AEs (that is, 
the last participant's last visit or LSLV).  
CONFIDENTIAL  
 TMF-[ADDRESS_371617] of clinical studies at 1 or more 
investigational sites.  
  
CONFIDENTIAL  
 TMF-17008580  
 218806  
19 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Protocol Title:  A Randomized, Double -Blind (Sponsor Unblinded), Placebo -Controlled, 
Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of 
VH4524184 in HIV -1 Infected Treatment Naïve Adults  
Brief Title: VH4524184 Proof -of-Concept in Treatment -Naïve Adults Living with HIV -1 
Rationale:  
VH4524184 is a  
 The in vitro 
antiviral potency of VH4524184  is comparable  
 with a likely high genetic barrier to resistance.  
This proof of concept (POC) study is designed to gain information on the antiviral effect, 
safety, tolerability and pharmacokinetic (PK) propertie s of VH4524184 orally 
administered to adults infected with HIV -[ADDRESS_371618] time in 
human (FTiH) study evaluating the safety, tolerability and PK prope rties of  
 VH4524184 in healthy participants and 218804 is a planned FTiH study 
evaluating the safety, tolerability and PK properties of  
VH4524184 in healthy participants. Study 218803 has shown VH4524184 to be g enerally 
well-tolerated in healthy participants to date ( 63 participants received VH4524184 as of 
27 Jul y 2023) and has thus far demonstrated a favorable PK profile suitable for 
progression to treatment -naïve (TN) adults with HIV -1 in this Phase 2a POC 10 -day, 
monotherapy study, .  
The data gathered from this study, together with data from the ongoing Phase 1 studies 
, will inform subsequent clinical trials and  
Phase 2b clinical development.   
  
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
20 Objectives, Endpoints, and Estimands:  
Objective(s)  Endpoint(s)  
Primary  
• To evaluate the antiviral activity of orally 
administered VH4524184 in TN participants with 
HIV-1 during 10 days of monotherapy  • Maximum change from  baseline (Day 1) in 
plasma HIV -1 ribonucleic acid (RNA) through 
Day 10.  
Secondary  
• To assess the safety and tolerability of orally 
administered VH4524184  • Incidence of adverse events (AEs), severity of 
AEs and proportion of participants who 
discontinue treatment due to AEs  
• Change from baseline and maximum toxicity 
grade increase from baseline for liver panel 
laboratory parameter ( Alanine Transaminase  
(ALT), Aspartate aminotransferase  (AST), 
total bilirubin, direct bilirubin, alkaline 
phosphatase, albumin  and total protein)  
• To characterize the pharmacokinetic profile of 
orally administered VH4524184  As data permits, PK measures that include:  
• Maximum observed plasma drug 
concentration (Cmax),  
• Time to maximum observed plasma drug 
concentration (tmax),  
• Concentration on Day 10  
• To evaluate any relationship between 
VH4524184 exposure and change in plasma HIV -
1 RNA  • Correlation of VH4524184 PK parameters 
with maximum plasma HIV -1 RNA change 
from baseline through Day 10  
• To assess the occurrence of emergent genotypic 
or phenotypic resistance after 10 days of 
monotherapy with VH4524184  • Genotypic and phenotypic data from baseline 
(Day 1) and Day 10 will be compared for 
amino acid substitutions and VH4524184 fold 
change IC50.  
• To assess the immunologic effects of VH4524184 
when administered over 10 days in participants 
living with HIV  • Change from baseline in CD4+ T -cell count to 
Day 10  
Tertiary  
• To further assess the safety and tolerability of 
orally administered VH4524184  • Post baseline values and changes over time 
of vital signs, electrocardiogram ( ECG ) 
parameters and suicidality scores.  
• Absolute values, change from baseline and 
maximum toxicity grade increase from 
baseline for hematology, coagulation and 
remaining chemist ry panels  
 
Overall Design:  
This is a Phase 2a POC, multi -center, randomized, double -blind (sponsor unblinded), 
placebo -controlled, adaptive clinical study to evaluate the antiviral effect, safety, 
tolerability and PK/PD of orally administered VH4524184 ov er 10 days in up to 
approximately 28 antiretroviral therapy (ART) naive adults with HIV -1 and detectable 
viremia.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
21 This study will be conducted in 2 parts. In Part 1, 21 treatment naïve (TN) participants 
will be randomized to [ADDRESS_371619] of Part 2 is dependent on the informal interim 
evaluation of the exposure -antiviral response data from Part  1 using available preliminary 
clinical data from Part 1. Interim analysis of Part 1 will determine if e valuation of a fourth 
dose of VH4524184 would be informative to properly characterize the exposure -antiviral 
relationship. If evaluation of a fourth dose is needed, Part 2 will be conducted and will 
include 1 additional cohort in which up to 6 participants  would receive VH4524184 and 1 
would receive matching placebo. Part 2 may evaluate 1 additional dose, with the dose and 
frequency informed by [CONTACT_31577]/PD modelling of Part 1 data .  
In both Part 1 and Part 2, each dose of VH4524184 will be evaluated as double -blind 
(Sponsor unblinded) monotherapy for 10 days (primary endpoint). On Day 10, participants 
will start open -label standard -of-care (SOC) antiretroviral therapy (ART) that is selected 
by [CONTACT_303806]. Participants will be followed wee kly through 
Day 38.  
 
  
All participants will be screened for elig ibility preferably within approximately 7 to 14 
days before being randomized into a 10 -day study intervention period. The screening 
period may be extended to 28 days to allow, at a minimum, receipt of all screening results 
and/or to accommodate scheduling.  
Following screening, the study requires a total of 9 in-clinic visits  (5 in-clinic visits  will 
occur  in the Monotherapy Period; 4 in -clinic visits  will occur  in the Open Label Follow -
Up Period)  and 3 virtual visits ( 3 virtual visits  will occur  in the Mono therapy Period; 
participant may choose to attend the visit in -clinic and this is acceptable).  
 
  
If participants prematurely discontinue the study fo r non -safety reasons, additional 
participants may be recruited with randomization and assignment to the same cohort (to 
ensure a minimum of 5 evaluable participants in each of cohorts 1, 2 and 3, and optional 
cohort 4) at the discretion of the Sponsor in c onsultation with the Investigator. Participants 
will not be replaced if the reason for discontinuation is the original participant meeting 
stoppi[INVESTIGATOR_3418].  
Total duration of study participation is approximately 45 to 66 days based on the 
following:  
• Screening Period:  7 to 14 days, with a maximum of 28 days permitted in some 
cases for screening/qualification period.  
• Monotherapy Period:  10 days for treatment with the study intervention and 
assessment at all planned visits.  
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
22 • Open Label Follow -up Period:  28 days for follow up visits while on SOC ART 
including the final follow up visit.  
See Section 1.3 (Schedule of Activities) for additional details  of activities during 
screening, the monotherapy period and the standard of care (SOC) period.  
Number of Participants:  
Approximately 28 antiretroviral therapy (ART) naïve  participants  may be enrolled in this 
study.  Part 1 of the study will enroll approximately 21 participants. If Part 2 of the study 
is conducted, approximately 7 additional participants will be enrolled.  
Data Monitoring/Other Committee:   
A safety review team ( SRT) is in place for each V iiV Healthcare  product. It comprises of 
a global cross -functional team responsible for the ongoing assessment of benefit -risk for a 
product. The SRT contribute to the continual blinded assessment of incoming new 
efficacy, safety and PK in formation. An external data and safety monitoring committee is 
not utilized in this study due to the relatively small size and early phase of the trial. This is 
further supported by [CONTACT_103682] -clinical 
toxicity studies and preliminary clinical study of VH4524184.  
ViiV Healthcare Safety and Labelling Committee  (VSLC) is a governance group that will 
review data and the team’s recommendation when any pausing/stoppi[INVESTIGATOR_26501]. The 
VSLC will govern whethe r enrollment may be resumed/modified, a given treatment arm 
will be stopped, or the study stopped. The VSLC is comprised of senior representatives 
from various departments, including clinical development, safety, toxicology, 
pharmacovigilance, epi[INVESTIGATOR_623] , and medical affairs.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
23 1.2. Schema   
Figure 1 Study design overview  
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
24 1.3. Schedule of activities (SoA)  
The schedule of study visits and expected study procedures and activities are detailed in 
Table 1 (Screening Period, Monotherapy Period) and Table 2 (Open Label Follow -up 
Period and Early Discontinuation Visit).  
While unlikely, the timing of assessments in Part 2 may be adjusted based on the interim 
analyses of the PK and/or antiviral results to ensure appropriate monitoring (e.g., to 
obtain data closer to the time of peak plasma concentrations or to maximal viral load 
decline). Any non -safety driven changes in the  timing of the planned study assessments 
will be documented and communicated to investigators but will not constitute a protocol 
amendment.  
Any emerging safety issues that constitute a substantial amendment and require alteration 
of the safety monitoring s cheme or amendment of the ICF will be approved by 
[CONTACT_103684]/IRBs before implementation.  
 
CONFIDENTIAL  
 TMF-17008580  
 218806  
 25 1.3.1.  Screening and Monotherapy Period  
Table 1 Screening and Monotherapy Period Schedule of Activities  
Clinical Procedures  Screening  VH4524184 Monotherapy Treatment Period (Double Blind)  
Day 1→Day 10   
  Visit  
1 Visit  
2 Visit  
3 Visit  
4 Visit  
5 Visit  
6 Visit  
7 Visit  
8  
 ~7 to 14 days 
before Day 1  Day  
1  Day  
2 Day  
3 Day  
4 Day  
5 Day  
6 Day  
7 Day  
8 Day  
9 Day 
10 Notes  
 Screening : In an effort to minimize delays to starting the open -label standard -of-care combination antiretroviral regimen, the screening period will be conducted in as short a time as 
possible and ideally w ithin 14 days. However, if necessary, screening period may be extended up to 28 days to allow receipt of all screening result s and/or to accommodate scheduling.  
Visits  
Outpatient visit  D10 The Monotherapy Treatment Period requires a minimum 
of 8 visits over a 10 -day period.  
• Days 1, 2, 3, 4, 7 and 10 are fixed visits. No window.  
• Visit 5 may be conducted on Day 5 or 6. 
• Visit 7 may be conducted on Day 8 or 9.  
• Assessments at Visit 3 (Day 3), Visit 5 (Day 5 or Day 
6), and Visit 7 (Day 8 or Day 9), may be conducted 
by [CONTACT_303807], 
although the participant may choose to attend the 
visit in t he clinic,  and this is acceptable.  
• Day 10: Complete all Day [ADDRESS_371620] of care ART.  
The visit schedule for each participant will be pre -
planned and weekend, work schedules, and clinic hours 
will be appropriately consider ed.   
Order of assessments : Assessment s, should occur in 
the following order:  
1) ECG  (if applicable) ; 2) Vital sign assessment; (3) 
eCSSRS; 4) Blood draw  (on PK days, HIV RNA to be 
collected at same time as pre -dose PK sample [with no Telephone call  
(Clinic visit allowed)  . . . D3  D5 or D6 . D8 or D9 . 
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 26 Clinical Procedures  Screening  VH4524184 Monotherapy Treatment Period (Double Blind)  
Day 1→Day 10   
  Visit  
1 Visit  
2 Visit  
3 Visit  
4 Visit  
5 Visit  
6 Visit  
7 Visit  
8  
 ~[ADDRESS_371621] ])   
 All Day [ADDRESS_371622] of care ART.  
Clinical and Other Assessments  
Informed consent  S . . . . . . . . . .  
Confirmation of no 
prior use of Anti -
retroviral Therapy  S D1 . . . . . . . . .  
Inclusion / Exclusion 
Criteria  S D1 . . . . . . . . . See Section  5.1 and Section 5.2 
Demography  S . . . . . . . . . .  
Medical History  S D1 . . . . . . . . . Smoking history and alcohol intake to be included within 
the review of medical history.  
See Section 8.1.2  
CDC HIV 
Classification  S D1 . . . . . . . . . See Section 10.7: Appendix 7.  
12-lead ECG  S D1 . . . . . . . . . ECG obtained locally (site). QT interval corrected for 
heart rate according to Fridericia’s formula (QTcF).  
• Screening :  Collect single  ECG reading to 
determine eligibility. A single repeat is allowed, if 
needed.  
See Section  7.1.3 , Section 8.3.3 . 
Vital Signs  S D1 D2 . D4 . . D7 . . D10 Body temperature, pulse rate, respi[INVESTIGATOR_697], and 
blood pressure will be recorded (before blood collection 
for laboratory tests). See Section 8.3.2 . 
eCSSRS suicidality  S . . . . . . . . . D10 See Section 8.3.6 . 
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 27 Clinical Procedures  Screening  VH4524184 Monotherapy Treatment Period (Double Blind)  
Day 1→Day 10   
  Visit  
1 Visit  
2 Visit  
3 Visit  
4 Visit  
5 Visit  
6 Visit  
7 Visit  
8  
 ~7 to 14 days 
before Day 1  Day  
1  Day  
2 Day  
3 Day  
4 Day  
5 Day  
6 Day  
7 Day  
8 Day  
9 Day 
10 Notes  
Physical exam  S (c)  D1 (b)  D2 (b)  . . . . . . . D10 (b) Complete  (c) physical exam to be performed at 
Screening and Day 38 or at Early Discontinuation  (ED) 
and will include assessments of the skin, cardiovascular, 
respi[INVESTIGATOR_696], gastrointestinal, and neurological systems.  
Brief (b) physical exam to be performed at Day 1, Day 2,  
and Day 10, and may be targeted to include , at a 
minimum, assessments of the skin, lungs, 
cardiovascular system, and abdomen (liver and spleen).  
At the discretion of the investigator, a brief physical 
examination may be made a complete physical 
examination.  
Any abnormalities to be recorde d as AEs.  See Section 
8.3.1  
Height, Weight, BMI  S . . . . . . . . . D10 Height, and weight to be measured at screening to 
calculate BMI. Height from screening can be used to 
calculate BMI on Day 10, Day 38/ED.  
AE/SAE assessment  S D1 D2 D3 D4 D5 or D6 D7 D8 or D9 D10 • AE/SAE assessment , HIV-associated conditions, and 
concomitant medication reviews  must be conducted 
with a participant during each day indicated. On the 
day when the participant does not come to the clinic, 
these assessments can be done via telephone.   
• Non-serious AEs are a ssessed from the time of first 
dose.  
• Serious AEs (SAEs) are assessed from the time of 
signing informed consent until the final visit in the 
Follow -up Phase.  HIV-associated 
conditions  S D1 D2 D3 D4 D5 or D6 D7 D8 or D9 D10 
Concomita nt 
medication review  S D1 D2 D3 D4 D5 or D6 D7 D8 or D9 D10 
  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 28 Laboratory Assessments  
Hepatitis B and C 
serologies  S . . . . . . . . . . See Appendix 10.2 for details of clinical laboratory tests.  
Syphilis RPR   S . . . . . . . . . .  
Drug, alcohol and 
cotinine screening  S . . . . . . . . . .  
Follicle stimulating 
hormone and 
estradiol  S . . . . . . . . . . To be completed as needed in participants (female sex 
assigned at birth) of nonchildbearing potential (PONCBP)  
to confirm post -menopausal status.  
Pregnancy Test  S (s)  D1 (u)  D2 (u) . D4 (u) . . . . . D10 (u) To confirm that participants (female sex assigned at 
birth) of childbearing potential are not pregnant. (s)= 
serum; (u) urine. If urine test cannot be confirmed as 
negative, a serum test is required.  
Plasma for HIV -1 
genotype/phenotype  S D1 D2 . D4 . . D7 . . D10  
Lymphocyte T -cell 
subsets (CD4, CD8)  S D1 . . . . . . . . D10  
Hematology / 
Chemistry / 
Coagulation/ Urine  S D1 D2 . D4 . . D7 . . D10 See Appendix 10.[ADDRESS_371623] or where 
quantity is insufficient for testing. In the event samples 
are not used by [CONTACT_90142], they may be utilized 
for additional research on antiretroviral resistance and/or 
HIV-1 disease biology/host immune response.   
HIV-1 RNA  S D1 D2 . D4 . . D7 . . D10 
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 29 Plasma PK sampling  
 Study Treatment  
Interactive Web 
Response System for 
Central 
Randomization  . D1 . . . . . . . . .  
VH4524184/placebo 
administration  
Dispensation of 
standard of care ART  . . . . . . . . . . D10 Standard of care antiretroviral therapy (SoC ART) will be 
chosen by [CONTACT_093]. The first dose of SoC ART 
will be at Day 10, after the completion of all Day 10 
assessments. Choice of SoC ART will be informed by 
[CONTACT_303808] , accepted clinical practice  and 
accessibility.  
If allowed per local regulatory guid elines and desired by 
[CONTACT_143062], SoC treatment will be 
continued for up to an additional 3 months following 
completion of follow -up assessments (post Day 38)  
Adherence 
counselling  . . . . . . . . . . D10 Adherence counseling may be provided by [CONTACT_133044]/or 
pharmacy staff consistent with local standards of care 
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 30 and site SOPs. Counseling should be provided in a 
participant -centered manner, tailored as needed to the 
information, skills building, and support needs of each 
participant. Discussions to be documented within site 
source files.  
AE= Adverse Events; (b)= Brief physical exam; BMI= Body Mass Index; (c)= Complete physical exam; CDC= Centers for Disease Con trol and Prevention;  D1= Day 1; D2=Day 2; D3=Day 3; D4=Day 4; 
D5=Day5; D6=Day 6; D7= Day 7; D8=Day 8; D9= Day 9; ECG= electrocardi ograph; HIV -1= human immunodeficiency virus type 1; (i)= Intensive PK visit;  PK= Pharmacokinetic RNA= ribonucleic acid; SAE= 
Serious Adverse Events; S= Screening; Standard of Care antiretroviral therapy = SoC ART; VH4524184=Investigational Product  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 31 1.3.2.  Open Label Follow -up Period  
Table 2 Open Label Follow -up Period Schedule of Activities  
Clinical Procedures  Open Label Follow -Up Period  Early 
Discontinuation   
Visit 9  Visit 10  Visit 11  Visit 12  
 Notes  Day 17 
(+/- 2 day)  Day 24 
(+/- 2 day)  Day 31 
(+/- 2 day)  Day 38  
(+/- 2 days)  
Visits  
Outpatient visit  D17 D24 D31 D38 ED Early Discontinuation: Additional follow -up visits/contacts beyond Day 38 are permitted if 
a participant experiences a safety event that requires follow -up monitoring.  
Clinical and Other Assessments  
12-lead ECG  . . . D38 ED 12-lead ECG schedule: Day 38 or at Early Discontinuation - single reading.  
Vital Signs  D17 D24 D31 D38 ED  
eCSSRS suicidality  . . . D38 ED  
Physical exam   D17 (b)  D24 (b)  D31 (b)  D38 (c)  ED (c)  Complete (c) physical exam to be performed at Screening and Day 38 or at Early 
Discontinuation and will include assessments of the skin, cardiovascular, respi[INVESTIGATOR_696], 
gastrointestinal, and neurological systems.  
Brief (b) physical exam to be performed at Day 17, Day 24 and Day 31, and may be 
targeted to include, at a minimum, assessments of the skin,  lungs, cardiovascular 
system, and abdomen (liver and spleen).  At the discretion of the investigator, a brief 
physical examination may be made a complete physical examination . 
See Section 8.3.1 .  
Any abnormalities to be r ecorded as AEs.  
Height, Weight, BMI  . . . D38 ED Height and weight to be measured at screening to calculate BMI. Height from screening 
can be used to calculate BMI on Day 10, Day 38/ED . 
AE/SAE assessment  D17 D24 D31 D38 ED • AE/SAE assessment, HIV -associated conditions, and concomitant medication review 
must be conducted with a participant during each day indicated.  
• Non-serious AEs are assessed from the time of first dos e. 
• Serious AEs (SAEs) are assessed from the time of signing informed consent until the 
final visit in the Follow -up Phase.  HIV-associated conditions  D17 D24 D31 D38 ED 
Concomitant medication 
review  D17 D24 D31 D38 ED 
CONFIDENTIAL  
 TMF-17008580  
 218806  
 32 Clinical Procedures  Open Label Follow -Up Period  Early 
Discontinuation   
Visit 9  Visit 10  Visit 11  Visit 12  
 Notes  Day 17 
(+/- 2 day)  Day 24 
(+/- 2 day)  Day 31 
(+/- 2 day)  Day 38  
(+/- 2 days)  
Laboratory Assessments  
Pregnancy Test  D17(u)  D24(u)  D31(u)  D38(u)  ED(u)  (s)= serum; (u) urine. If urine test cannot be confirmed as negative, a serum test is 
required.  
Plasma for HIV -1 
genotype/phenotype  . . . . ED  
Lymphocyte T -cell subsets 
(CD4, CD8)  . . . D38 ED  
Hematology / Chemistry / 
Coagulation/ Urine  D17 D24 D31 D38 ED See Appendix 2, Section 8.3.[ADDRESS_371624] or where quantity is insufficient for testing. In the event samp les are not 
used by [CONTACT_90142], they will be utilized for additional research on antiretroviral 
resistance and/or HIV -1 disease biology/host immune response. See Section 8.8 for 
more details.  
HIV-1 RNA  . . . D38 ED  
Plasma PK sampling  To be collected at the same time as HIV -1 RNA samples (with no preference as to which 
is drawn first).  
Standard of Care ART  
Dispense standard of care 
ART D17 D24 D31 D38 ED Standard of care antiretroviral therapy (SoC ART) will be chosen by [CONTACT_093]. 
Choice will be informed by [CONTACT_303808] , accepted clinical practice  and 
accessibility. If allowed per local regulatory guideline s and desired by [CONTACT_303809], standard -of-care treatment will be continued for up to an additional 3 
months following completion of follow -up assessments (post Day 38)  
Adherence counselling  D17 D24 D31 D38 ED Adherence counseling may be provided by [CONTACT_133044]/or pharmacy staff consistent with 
local standards of care and site SOPs. Counseling should be provided in a participant -
centered manner, tailored as needed to the information, skills building, and support 
needs of each participant. D iscussions to be documented within site source files.  
AE= Adverse Events; (b)= Brief physical exam; ART= antiretroviral therapy; BMI= Body Mass Index; (c)= Complete physical exam;  D10= Day 10; D17=Day 17; D24=Day 24; D31=Day 31; D38=Day 38; 
ECG= electrocardiograph; ED=Early Discontinuation; HIV -1= human immun odeficiency virus type 1; PK= Pharmacokinetic RNA= ribonucleic  acid; SAE= Serious Adverse Events : Standard of care 
antiretroviral therapy (SoC ART)
CCI
CONFIDENTIAL  
 TMF-[ADDRESS_371625] yet to initiate treatment.  
Clinical development of VH4524184 is ongoing.  Study 218803 is an ongoing FTiH study 
evaluating the safety, tolerability and PK properties of  VH4524184 in 
healthy participants and 218804 is  a planned FTiH study evaluating the safety, 
tolerability and PK properties of  VH4524184 in healthy 
participants. Study 218803 has shown VH4524184 to be generally well -tolerated in 
healthy participants to date ( 63 participants received VH4524184 as of 27 Jul y 2023) and 
has thus far demonstrated a favorable PK profile suitable for progression to TN adults 
with HIV -1 in this Phase 2a POC 10-day, monotherapy study,  
  
The data gathered from this study, togethe r with data from the ongoing Phase 1 studies 
, will inform subsequent clinical trials and 
Phase 2b clinical development.   
2.2. Background  
2.2.1.  Unmet Medical Need  
Globally, approximately 3 9 million people are currently livi ng with HIV/AIDS. This 
worldwide epi[INVESTIGATOR_103624] a rate of 1. 3 million new infections and causes 
0.6 million deaths per year[UNAIDS , 2023 ]. HI V-1 treatment requires life -long therapy 
with a minimum of two antiretroviral (ARV) medicines with different mechanisms of 
action.   
Management of HIV chronically is associated with long -term toxicity of anti -retroviral 
therapy (ART) as well as the possibility of development and transmission of resistant 
virus. Long -term toxicities may impact the CNS, CV system, alterations in metabolis m 
and impaired renal function. Regimens which avoid particular classes of agents may help 
avoid or manage comorbidities among persons with HIV (PWH) and the use of treatment 
regimens with fewer medicines have the potential to reduce long -term toxicities by  
[CONTACT_303810]. Treatment failure remains a continuing concern in clinical care 
due to the presence and emergence of resistant strains and tolerability issues. In addition, 
managing an aging population of PWH with an increasing prevalence of comorb idities 
and polypharmacy requires ARVs with the potential for fewer drug -drug interactions.  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 34 ARVs are notably effective, having converted an inevitably fatal infection into a chronic 
condition, but there is an opportunity for developi[INVESTIGATOR_303773] d osed and better 
tolerated ARV regimens. There remains on -going need for new ARV agents with 
improved safety and tolerability.  
 
 
 
 
 
 
  
 
 
  
Summaries of the non -clinical studies of VH4524184 and safety and PK  clinical data 
 of VH4524184 in study 218803 are included in the IB [[COMPANY_004] 
Document No RPS-CLIN -069016 ].  
The safety and pharmacokinetic pro file of  VH4524184 are being 
characterized in healthy volunteers in the ongoing study 218803.    
[IP_ADDRESS].  Study 218 803 –  FTiH VH4524184  
Study 218803 is a double -blind (sponsor -unblinded), randomized, placebo -controlled, 
FTIH study in a combined single - and multiple -dose protocol to investigate the safety, 
tolerability and PK of VH4524184 in healthy participants  [[COMPANY_004] Document Number 
TMF -16041100 ]. This study is designed to evaluate:  
• the safety, tolerability, and PK  properties of VH4524184 when administered  as 
single and multiple ascending dosing   
• the safety, tolerability, and PK of the VH4524184   
•   
• any effect of VH4524184 on the activity of CYP3A using midazolam as a probe.  
Dose -proportional increases in geometric mean plasma concentrations of VH4524184 
were observed      
, without further increases in exposure following  
. VH4524184 geometric mean observed time to maximum 
concentration and half -life were  
 
 
 
 
 
 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-[ADDRESS_371626] been no clinically significant safety findings, SAEs, deaths, trends in 
vital signs, laboratory parameters, ECG parameters nor discontinuati ons due to AEs.  
Forty -five participants  were exposed to single doses of VH4524184 or placebo in the 
SAD  part of the study. Twelve participants experienced a t otal of 1 7 AEs, the majority of 
which were mild in severity , per the Investigator, except for  an AE of back pain  
(moderate) . Three participants experienced AEs considered by [CONTACT_303811], these included 2 reports of constipation ( 1 in  and 
1 in , both mild in severity per the Investi gator) and AEs of eye pain 
and headache in a participant in the .   
Twenty -seven participants were exposed to  VH4524184  or placebo  in 
the MAD part of the study . Thirteen participants expe rienced 21 AEs , all of which were 
mild, per the Investigator,  except for 3 moderate AEs (all unrelated: headache,  
abdominal pain and rib  fracture ). One participant exp erienced 2 AEs of fatigue, which 
were considered by [CONTACT_7185].  
 
. The treatment periods were separated 
by  [CONTACT_303812] . Four participants exp erienced 6 AEs, all of 
which were mild. One participant experienced  an AE of diarrhea on study Day 1, which 
was considered by [CONTACT_66325].  
2.3. Benefit/risk assessment  
Pre-clinical safety assessment studies together with  safety and PK clinical data  
 of VH4524184 in stud y 218803, which are summarized in the VH4524184 
IB [[COMPANY_004] Document Number [RPS-CLIN -069016 ], have not highlighted any issues with 
the potential to impact safety in humans. The clinical parameters which will be monitored 
throughout the study, as described in the SoA (Section 1.3), are based primarily on ADRs 
which have been observed , both during clinical development and from 
post-marketing experience. For  
 
  
To ensure the overall safety of participants (including, but not limited to, the potential 
risks as outlined in the table below), this clinical trial will include relativ ely healthy 
treatment -naïve adults living with HIV -1 who will be actively monitored by [CONTACT_303813], ECG, and laboratory evaluations during their participation in the trial .  
More detailed information about the known and expected benefits an d risks and 
reasonabl y expected AEs of VH4524184 may be found in the IB.  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 36 2.3.1.  Risk assessment  
Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Study Intervention VH4524184  
Hepatotoxicity   Clinical trials have shown that elevations of 
liver enzymes and/or hepatitis can potentially 
occur with ; these 
events are uncommon. No hepatotoxic events 
attributed to VH4524184 were observed in  
FTIH Study 218803.  Standard M edical Monitoring practices and 
Clinical Safety Data Review processes including 
review of relevant emerging data.  
Use of protocol defined measures to minimize  the 
risk of hepatotoxicity in subjects i.e., specific 
exclusion criteria based on screening hepatic 
transaminases (ALT/AST values), detailed liver 
stoppi[INVESTIGATOR_303774], see  
Appendix 10.5 for required actions and follow -up 
assessments in the event of liver stoppi[INVESTIGATOR_303775]).  
Informed consent f orms will include notification of 
the potential for hepatotoxicity.  
Depression (including suicidal ideation and 
behaviors, particularly in patients with a pre -
existing history of depression or psychiatric 
illness)  Depression and suicidal ideation and beha viors 
have been observed . These events 
occur particularly in patients with a pre -existing 
history of depression or psychiatric illness. 
 Participants with any history of major depressive 
disorder with or without suicidal features, or 
anxiety disorders, that required medical 
intervention (pharmac ologic or not) such as 
hospi[INVESTIGATOR_103631]/or 
chronic (>6 months) outpatient treatment will be 
excluded from the study.  
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 37 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
 provide the evidence for this 
risk. 
No psychiatric events were observed in  
FTIH Study 218803.  Participants in the study will undergo intensive 
physical exam and laboratory testing. In addition, 
partici pants will undergo continuous evaluation for 
all treatment -emergent adverse events, including 
those related to depression, anxiety, and suicidal 
ideation/behavior during their participation in the 
trial; there are clinical stoppi[INVESTIGATOR_303776] t-
emergent AEs.  
All participants will be administered th e CSSRS 
questionnaire  at screening, Day 10 , Day 38, or at 
Early Discontinuation . In the event of a positive 
CSSRS  (abnormal ) response confirmed by [CONTACT_1275], or other report of suicidal ideation  
and behavior  by [CONTACT_303814] , the PI/sub -investigator (SI) will arrange 
for urgent specialist  psychiatric evaluation and 
management.   
Informed co nsent forms will include notification of 
the potential for depression and suicidal 
ideation/behavior.  
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 38 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Hypersensitivity reactions (HSR)  Hypersensitivity is an uncommon but 
recogni zed risk for anti -retroviral regimens 
containing , 
regardless of dose. Hypersensitivity -type 
reactions have been . 
These reactions were characterized by [CONTACT_303815], and sometimes 
organ dysfunction, including liver injury.  
 
The cases which have been reported in 
association  have 
predominantly presented within angioedema 
and u rticaria. While a casual association with 
more severe or systemic hypersensitivity 
reactions has not been identified with 
 to date, there remains a 
theoretical risk of such reactions with or without 
hepatic symptoms.  
No events indicative of hypersensitivity were 
observed in Study 218803.  Standard Medical Monitoring practices and 
Clinical Safety Data Review processes including 
review of relevant emergin g data from ongoing 
studies.  
Participants with history of drug hypersensitivity, 
delayed -type hypersensitivity or severe 
hypersensitivity reactions, as well as history of 
hypersensitivity to the study drugs are excluded 
(Section 5.2).  
Specific/detailed toxicity management guidance 
for HSR is included in the protocol (Section  7.1.6 ).  
Informed consent forms will include notification of 
the potential for HSR.  
Co-medications  during the monotherapy phase 
should be limited to those that are medically 
necessary. Co -medications should be discussed 
with the ViiV medica l monitor.  
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 39 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
HIV Resistance to VH4524184  There is an intrinsic risk of resistance 
(genotypic changes or decreased phenotypic 
susceptibility) to any developmental ARV – 
particularly when given in monotherapy  
Prior  P roof of Concept studies : Data 
from the monotherapy studies for  
 showed a decline in HIV -1 RNA over the 
10 day treatment duration. No  
resistance associated mutations were observed 
and no resistance to existing and commercially 
available classes of antiretroviral medications 
(e.g., reverse transcriptase or protease 
inhibitors) was observed. Of note, there is no 
known cross -resistance between  and 
other classes of ARVs.  This Phase 2a study is limited to [ADDRESS_371627] use acceptable forms of non -
hormonal contraception through to Day 38. 
POCBP will hav e pregnancy testing conducted 
prior to study intervention and during the study.  
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 40 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Doses used in the Monotherapy Period have 
been studied in  F TIH study 218803.  
Supportive pre -clinical data  Participants who become pregnant after 
administration of the first study intervention dose 
must not receive subsequent doses of the study 
intervention but may continue other st udy 
procedures at the discretion of the investigator.  
 
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 41 2.3.2.  Benefit assessment  
This study in HIV -1 infected, TN and otherwise healthy participants is a short -term 
monotherapy design. There is no expected longer -term anti -HIV benefit to administration 
of VH4524184 during this study; however, participants will transition to standard of care 
ART on study Day 10. Potential delays in initiating combination ART as a result of 
partici pating in this study are expected to be short and are not expected to have any 
clinically relevant impact upon study participant outcomes.  
2.3.3.  Overall benefit -risk conclusion  
Given the preclinical profile of VH4524184, safety data obtained from VH4524184 study  
218803, the established safety profile of other  and the 
planned clinical procedures and evaluations in this study, the potential risks to adult 
participants with HIV -1 who are treatment naïve and otherwise relatively healthy 
receiving 10 days of VH4524184 monotherapy followed by [CONTACT_303816], evaluable, and 
manageable.  
To date, the benefit -risk profile of VH4524184  has been favorable  in the clinical 
development program, with no new key safety concerns identified that would preclude 
the ongoing investigations.  
Considering risk mitigation strategies incorporated into the study protocols or study 
management, the potential/identified risk s with use of VH4524184  are justified by [CONTACT_303817]; therefore, the benefit -risk profile of VH4524184  supports continued 
clinical development for the treatment of HIV -1 infection.  
 
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 42 3. OBJECTIVES, ENDPOINTS AND ESTIMANDS  
Table 3 Objectives and Endpoints  
 
Objective(s)  Endpoint(s)  
Primary  
• To evaluate the antiviral activity of orally 
administered VH4524184 in TN participants with 
HIV-1 during 10 days of monotherapy  • Maximum change from baseline (Day 1) in 
plasma HIV -1 RNA through Day 10.  
Secondary  
• To assess the safety and tolerability of orally 
administered VH4524184  • Incidence of AEs, s everity of AEs and proportion 
of participants who discontinue treatm ent due to 
AEs 
• Change from baseline and maximum toxicity 
grade increase from baseline for liver p anel 
laboratory parameter (ALT, AST, total bilirubin, 
direct bilirubin, alkaline phosphatase, albumin and 
total protein)  
• To characterize the pharmacokinetic profile of 
orally administered VH4524184  As data permits, PK measures that include:  
• Cmax,  
• tmax  
• Concentration on Day 10  
• To evaluate any relationship between 
VH4524184 exposure and change in plasma HIV -
1 RNA  • Correlation of VH4524184 PK parameters with 
maximum plasma HIV -1 RNA change from 
baseline through Day 10  
• To assess the occurrence of emergent genotypic 
or phenotypic resistance after 10 days of 
monotherapy with VH4524184  • Genotypic and phenotypic data from baseline 
(Day 1) and Day 10 will be compared for amino 
acid substitutions and VH4524184 fold change 
IC50.  
• To assess the immunologic effects of VH4524184 
when administered over 10 days in participants 
living with HIV  • Change from baseline in CD4+ T -cell count to 
Day 10  
Tertiary  
• To further assess the safety and tolerability of 
orally administered VH4524184  • Post baseline values and changes over time of 
vital signs, ECG parameters and suicidality 
scores.  
• Absolute values, change from baseline and 
maximum toxicity grade increase from baseline 
for hematology, coagulation and remaining 
chemistry panels  
 
  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 43 3.1. Primary estimand  
3.1.1.  Antiviral activity  
• The primary objective is to evaluate the antiviral activity of orally administered 
VH4524184 in TN participants with HIV -1 during 10 days of monotherapy. The 
estimand is described by [CONTACT_6570]:  
• Population:  
Overtly healthy (other than HIV -1 infection) treatment naïve individuals  
• Endpoint:  
Maximum change from baseline (Day 1) in plasma HIV -1 RNA through Day 10  
• Treatment:  
- VH4524184 or placebo  
• Intercurrent events : 
- Discontinuation of study tre atment due to any reason will be addressed using 
while on -treatment  strategy , i.e. any HIV -1 RNA data available after study 
treatment discontinuation day + [ADDRESS_371628] prior to Day 10, will be excluded from 
calculation of max VLD  
- Use of prohibited medication will be addressed using treatment policy strategy , 
i.e., any HIV -1 RNA data available after use of prohibited medication will be 
used in calculation of max VLD  
- 
• Population -level summary:  
Mean of maximum change from baseline in log10 HIV -1 RNA during Days 1 -10 
Ratio nale for estimand:  Interest lies in evaluating efficacy of orally administered 
VH4524184 , or use of prohibited medications and not 
in combination with other antiretroviral medication.  
3.2. Key secondary estimand(s)  
3.2.1.  Safety an d tolerability  
• The secondary objective is to assess the safety and tolerability of orally administered 
VH4524184. The estimand is described by [CONTACT_6570]:  
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 44 • Population:  
Overtly healthy (other than HIV -1 infection) treatment naïve individuals  
• Endpoints:  
- Incidence of AEs, s everity of AEs and proportion of participants who discontinue 
treatm ent due to AEs  
- Change from baseline and maximum toxicity grade increase from baseline for 
liver panel laboratory parameter  
• Treatment:  
VH4524184 or placebo  followed by [CONTACT_303818] 10 -38 
• Intercurrent events:  
- Discontinuation of study treatment due to any reason will be addressed using 
treatment policy strategy , i.e. all safety data after study treatment 
discontinuation will be used  
- Use of SOC medication prior to Day [ADDRESS_371629] prior to Day 10, will be excluded from monotherapy safety 
summaries  
- Use of prohibited m edication will be addressed using treatment policy strategy , 
i.e., all safety data will be used regardless of the use of prohibited medication  
- 
• Population -level  summary:  
AEs:  
- Number and percentage of partici pants with AEs  
- Number and percentage of partici pants with AEs by [CONTACT_86953]  
- Number and percentage of partici pants with AEs leading to study treatment 
discontinuation  
Liver panel laboratory parameters:  
- Summary statistics (mean, SD, median, min, max, etc.) of change from baseline  
- Number and percentage of participants with maximum toxicity grade increase 
relative t o baseline  
Rationale for estimand:  Interest lies in evaluating safety and tolerability of orally 
administered VH4524184 irrespective of study treatment discontinuation,  
, or use of prohibited medications and not in combination with othe r antiretroviral 
medication.  
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 45 3.2.2.  Pharmacokinetic profile  
Another secondary objective is to characterize the PK profile of orally administered 
VH4524184. The estimand is described by [CONTACT_6570]:  
• Population:  
Overtly healthy (other than HIV -1 infec tion) treatment naïve individuals  
• Endpoints: as data permits   
- Maximum observed plasma drug concentration (Cmax)  
- Time to maximum observed plasma drug concentration (tmax)  
- Concentration on Day 10  
• Treatment:  
VH4524184 or placebo  followed by  [CONTACT_303818] 10 -38 
• Intercurrent events:  
- Discontinuation of study treatment due to any reason will be addressed using 
while on -treatment strategy , i.e. PK data after study treatment discontinuation 
will be excluded from use in  noncompartmental  analyses.  
- Use of SOC medication prior to Day [ADDRESS_371630] prior to Day 10, will be excluded  
- Use of prohibited medication will be addressed using treatment policy strategy , 
i.e., all PK data will be used regardless of the use of prohibited medication  
-  of study treatment will be addressed using while on -
treatment strategy , i.e., PK data collected  will be 
excluded  from use in  noncompartmental analyses . 
• Population -level summary:  
Summary statistics (e.g. arithmetic mean, SD, median, min, max, geometric mean, 
SD (log), %CVb, etc.)  
Rationale for est imand : Interest lies in characterizing the PK profile of orally 
administered VH4524184 which could be biased by [CONTACT_303819], 
, or use of SOC medication prior to day 10.  
4. STUDY DESIGN  
4.1. Overall design  
This is a Phase 2a POC, multi -center, randomized, double -blind (sponsor unblinded), 
placebo -controlled, adaptive clinical study to evaluate the antiviral effect, safety, 
tolerability and PK/PD of orally administered VH4524184 over [ADDRESS_371631] of Part 2 is dependent on the informal interim 
evaluation of the exposure -antiviral response data from Part  1 using available preliminary 
clinic al data from Part 1. Interim analysis of Part 1 will determine if evaluation of a 
fourth dose of VH4524184 would be informative to properly characterize the exposure -
antiviral relationship. If evaluation of a fourth dose is needed, Part 2 will be conducted  
and will include 1 additional cohort in which up to 6 participants would receive 
VH4524184 and 1 would receive matching placebo. Part 2 may evaluate 1 additional 
dose, with the dose and frequency informed by [CONTACT_31577]/PD modelling of Part 1 data.   
In both Part 1  and Part 2, each dose of VH4524184 will be evaluated as double -blind 
(Sponsor unblinded) monotherapy for 10 days (primary endpoint). On Day 10, 
participants will start open -label SOC  ART that is selected by [CONTACT_303820]. Participants will be followed weekly through Day  38.  
 
  
All participants will be screened for eligibility preferably within approximately 7 to 14 
days before being randomized into a 10 -day study intervention period. The screening 
period may be extended to 28 days to allow, at a minimum, receipt  of all screening results 
and/or to accommodate scheduling.  
Following screening, the study requires a total of 9 in-clinic visits  (5 in-clinic visits will 
occur in the Monotherapy Period; 4 in -clinic visits will occur in the Open Label Follow -
up Period)  and 3 virtual visits  (3 virtual visits will occur in the Monotherapy Period; 
participant may choose to attend the visit in clinic and this is acceptable) .  
 
  
If participants prematurely discontinue the study for non -safety reasons, additional 
participants may be recruited with randomization and assignment to the same cohort (to 
ensure a minimum of 5 evaluable participants in each of cohorts 1, 2 and 3, a nd optional 
cohort 4) at the discretion of the Sponsor in consultation with the Investigator. 
Participants will not be replaced if the reason for discontinuation is the original 
participant meeting stoppi[INVESTIGATOR_3418].  
Total duration of study participation i s approximately 45 to 66 days based on the 
following:  
• Screening Period:  7 to 14 days, with a maximum of 28 days permitted in some 
cases for screening/qualification period . 
• Monotherapy Period:  10 days for treatment with the study intervention and 
assessment at all planned visits .  
• Open Label Follow -up Period:  28 days for follow up visits while on SOC ART 
including the final follow up visit.  
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 47 See Section 1.3 (Schedule of Activities) for additional details of activities during 
screening, the monotherapy period and the SOC  period.  
4.2. Scientific rationale for study design  
This is a Phase 2a, multi -center, randomized, double -blind (sponsor unblinded), placebo -
controlled, adaptive design, proof of concept clinical study to evaluate the antiviral effect, 
safety, tolerability, and PK/PD of [ADDRESS_371632] -of-care antiretroviral therapy selected 
by [CONTACT_303821]/approved  available data suggests that 
 resistance does not occur during short periods of  monotherapy; therefore, 
dosing with VH4524184 will not interfere with selection of the ART regimen selected by 
[CONTACT_98203] [ADDRESS_371633] number of HIV -infected 
participants. The placebo control maintains the blind, reduces bi as in the investigator's 
evaluation and management of safety events, and permits a comparison of safety and 
efficacy outcomes between the investigational product and placebo.  
The 2-part adaptive design will allow for interim evaluation of the exposure -antiviral 
response data to determine if evaluation of a  fourth dose of VH4524184 would be 
informative to properly characterize the exposure -antiviral relationship. If a fourth dose is 
not needed, then exposing additional participants to the investigational product can be 
avoided.  
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 48 4.2.1.  Participant input into design   
Community advisors living with HIV were engaged in development of this short -term 
monotherapy proof -of-concept study design . The group of highly experienced patient 
advocates provided feedback on protocol feasibility  and inform ed guidance for study 
implem entation  (such as considerations for assessment of site facilities, potential services 
to ease participant burden during longer visits and travel to site, potential inclusion of 
POCBP in the study population, and considerations for the development of the i nformed 
consent  document ).   
4.3. Justification for dose  
The p harmacokinetics following  VH4524184 has been  
characterized in study 218803  [IB, 2023 ]. The  cohort  in [ADDRESS_371634] dosing cohort in this study will be 
lower than what has been observed in 218803 and based on the tolerability and s afety 
profile in the FTiH  study, dosing in the PoC protocol is considered safe. A POP PK 
model was developed from participan t VH4524184 PK observations collected in study 
218803.  
. Details  for POP PK model 
development are described in the [ZIP_CODE] 4 Human Dose Prediction Report [[COMPANY_004] Study 
report TMF -16733560] . The POP PK model is being leveraged herein to simulate 
VH4524184 exposures that achieve desired trough concentrations across [ADDRESS_371635] trough concentra tions that  
  
Figure 2 Simulated Plasma concentrations of VH4524184 Achieved Following 
Dosing of   
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 49 The maximum reduction of HIV -1 RNA from baseline (~ 2 – 2.5 log10 reduction) has 
been  consistent across   [Markowitz , 2006; Min, 2011; Spreen , 2013; 
Gallant , 2017 ].  of VH4524184  is anticipated to achieve 
maximum Day 10 reduction of HIV -1 RNA from baseline  for all participants . Depending 
on the virologic response observed in the three planned cohorts , an additional cohort may 
be enrolled to further  describe the relationship between VH4524184 exposure and HIV-1 
RNA levels.  In this instance , PK/PD modeling will be used to inform the dose and 
frequency of the optional Part [ADDRESS_371636] participa nt in the 
study.  
Part 2 of the study is optional. Completion of the study at the end of Part 1 will not be 
considered an early termination.  
5. STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.  
 Approximately 28 TN participants who are viremic at baseline (confirmed HIV -1 RNA 
≥ 3,000  copi[INVESTIGATOR_014]/mL) and have CD4 T -cell counts ≥200 c/µL will be recruited.  Part 1 of the 
study will enroll approximately 21  participants. If Part 2 of the study is conducted, 
approximately 7 additional participants will be enrolled.  
All participants will be screened for eligibility preferably within approximately 7 to 14 
days. The screening period may be extended to 28 days to  allow, at a minimum, receipt 
of all screening results and/or to accommodate scheduling. If the screening period last s 
beyond 14 days, notification of the medical monitor is required.  
5.1. Inclusion criteria  
Participants are eligible to be included in the study only if all of the following 
criteria apply:  
1. Participant must be 18 to 65 years of age inclusive at the time of signing the informed 
consent.  
2. Participants who are overtly healthy (other than HIV infection) as determined by [CONTACT_303822] a medical evaluation including 
medical history, physical examination, laboratory tests, and cardiac monitoring.  
3. Positive HIV antibody test  
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 50 4. Documented HIV infection and Screening plasma HIV-1 RNA ≥  3,000  copi[INVESTIGATOR_014]/mL.  A 
single r epeat of this test is allowed within a single Screening period to determine 
eligibility.  
5. Screening CD4+ T -cell count ≥200 cells/mm3  
6. Treatment -naïve: No antiretrovirals (ARVs, in combination or monotherapy) received 
after the diagnosis of HIV -[ADDRESS_371637] -exposure prophylaxis: No prior use of any INSTI 
(including cabotegravir) for HIV pre -exposure or post -exposure prophylaxis.  
8. Body weight ≥50.0 kg (110 lbs.) for men and ≥45.0 kg (99 lbs) for women and BMI 
within the range 18.5 -31.0 kg/m2 (inclusive - applies to males and females).  
9. All participants in the study should be counselled  on safe sexual practices including 
the use and benefit/risk of effective barrier methods (e.g., male condom) and on the 
risk of HIV transmission to an uninfected partner.  
10. Male or female    
a. Male Participants:   
• No restrictions for male participants   
b. Fe male Participants:   
• A female participant (female sex assigned at birth) is eligible to participate 
if she is not pregnant or breastfeeding , and 1 of the following condition s 
applie s:  
• Is a PONCBP as defined in Section [IP_ADDRESS] .  There is no requirement for 
PONCBP to use a highly effective method of contraception or complete 
pregnancy testing . 
OR 
• Is a POCBP and is using a non -hormonal contraceptive method that is 
highly effective (failure rate of <1% per year when used consistently and 
correctly) as described in Section 10.4.[ADDRESS_371638] visit in the Follow -up Period (Day 38).   The Investigator should 
evaluate potential for contraceptive method failure (e.g ., noncompliance, 
recently initiated) in relationship to the first dose of study intervention.  
11.  A participant of childbearing potential must have a negative serum hCG test at 
screening , and negative urine hCG test at Day [ADDRESS_371639] dose of study 
intervention. See Section 8.3.5 , Pregnancy testing .   
CONFIDENTIAL  
 TMF-17008580  
 218806  
 51 • If a urine test cannot be confirmed as negative (e.g. ambiguous result), a 
serum pregnancy test is required.  In such cases, the participant must be 
excluded from participation if the serum pregnancy result is positive.  
• The Investigator is responsible for review of medical history, menstrual 
history, and recent sexual activity to decrease risk for inclusion of a 
female with an early undetected pregnancy.  
12. Capable of giving signed informed consent as described in Section 10.1.[ADDRESS_371640] -of-care ART as selected with 
the investigator on Study Day 10.  
5.2. Exclusion criteria  
Participants are excluded from the study if any of the following criteria apply:  
5.2.1.  Medical Conditions  
1. Participants with primary HIV infection, evidenced by [CONTACT_103698] 
(e.g., fever, malaise, fatigue, etc) and/or evidence of recent (within 3 months) 
documented viremia without antibody production and/or evidence of recent (within 3 
months) documented seroconversion.  
2. Any evidence of an  active CDC Stage 3 disease [ CDC , 2014],  except cutaneous 
Kaposi’s sarcoma not requiring systemic therapy during the study.   
3. Untreated syphilis infection [positive RPR at screen ] without documentation of 
treatment.  Participants who have successfully completed treatment at least 7 days 
previously are eligible if recruitment is open.  
4. Ongoing malignancy other  than cutaneous Kaposi's sarcoma, basal cell carcinoma, 
or resected, non -invasive cutaneous squamous cell carcinoma, or cervical, anal or 
penile intraepi[INVESTIGATOR_28601]; or other localized malignancies require agreement 
between the investigator and the study medical monitor for inclusion of the 
participant prior to randomizati on. Treatment with radiation therapy or cytotoxic 
chemotherapeutic agents within [ADDRESS_371641] igator, may interfere with the participant’s ability to comply with the dosing 
schedule and/or protocol evaluations or which may compromise the safety of the 
participant.  
6. Any history of significant underlying psychiatric disorder, in the opi[INVESTIGATOR_303777], including but not limited to schizophrenia, bipolar 
disorder with or without psychotic symptoms, other psychotic disorders, or 
CONFIDENTIAL  
 TMF-17008580  
 218806  
 52 schizotypal (personality) disorder; or a clinical assessment of suicidality based on the 
responses on the eCSSRS.  
7. Any history of major depressive disorder with or without suicidal features, or anxiety 
disorders, that required medical intervention (pharmacologic or not) such as 
hospi[INVESTIGATOR_103631]/or chronic (>6 months) outpa tient 
treatment. Participants with other conditions such as adjustment disorder or 
dysthymia that have required shorter term medical therapy (<6 months) without 
inpatient treatment and are currently well -controlled clinically or resolved may be 
considered for entry after discussion and agreement with the Medical Monitor.  
8. 
9. Current or chronic history of liver disease or known hepatic or biliary abnormalities 
(with the exception of Gilbert's syndrome or asymptomatic gallstones).  
10. Medical history of cardiac arrhythmias or cardiac disease or a family or personal  
history of long QT syndrome or sudden cardiac death. Any significant arrhythmia or 
ECG finding (e.g., prior myocardial infarction, sinoatrial pauses, bundle branch 
block, or conduction abnormality) which, in the opi[INVESTIGATOR_303778], will interfere with the safety for the individual participant.  
11. Exclusion criteria for screening ECG (a single repeat is allowed for eligibility 
determination  and will be the screening ECG ent ered into the eCRF ):  
   Males   Females   
Heart rate1  <45 or >100 
bpm  <50 or >100 bpm   
PR interval   <120 or >200 msec   
QRS duration   <70 or >110 msec   
QTcF interval  2,3  >450 msec   >470 msec  
1 A heart rate from 100 to 110 bpm can be rechecked by [CONTACT_303823] 30 minutes to verify eligibility.   
2 QTcF > 480 msec in participants with bundle branch block.  
3 The QTc is the QT interval corrected for heart rate according to Fridericia’s formula (QTcF), it is either 
machine -read or manually over -read.  The specific formula that will be used to determine  eligibility and 
discontinuation for an individual subject will be determined prior to initiation  of the study - QTcF will be used 
for this study. In other words, several different formulae cannot be used to calculate the QTc for an 
individual subject and then the lowest QTc value used to include or discontinue the subject from the trial.   
To assess any potential impact on participant eligibility with regard to safety, the 
investigator must refer to the IB and supplements, approved product labels, and/or lo cal 
prescribing information for detailed information regarding warnings, precautions , 
contraindications, AEs, drug interactions, and other significant data pertaining to the 
study drugs.  
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 53 5.2.2.  Prior/Concomitant Therapy   
12. Treatment with immunomodulating agents (such as systemic corticosteroids, 
interleukins, interferons) or any agent with known anti -HIV activity (such as 
hydroxyurea or foscarnet) within [ADDRESS_371642] or intended use of over -the-counter or prescription medication  including herbal 
medications within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 
half-lives (whichever is longer) prior to dosing. Specific medications listed in Section 
6.9.1  may be allowed.  
14. History of sensitivity to any of the study medications, or their components or drugs of 
their class, or a history of drug hypersensitivity (including delayed hypersensitivity or 
severe hypersensitivity rea ctions)  or other allergy that, in the opi[INVESTIGATOR_303779], contraindicates their participation.  
15. Participants who require concomitant medications known to be associated with a 
prolonged QTc.   
16. Participants receiving any protocol -prohibited medication(s) and who are unwilling or 
unable to switch to an alternate medication (See Section  6.9.2 ). 
5.2.3.  Prior/Concurrent Clinical Study Experience  
17. The participant has ever received an investigational HIV vaccine 
(immunotherapeutic or immunomodulatory).  
18. Exposure to an experimental drug or expe rimental vaccine within either [ADDRESS_371643] dose of study intervention.  
• Note: Receipt of a SARS -CoV -[ADDRESS_371644] 14 days  
prior to study entry (i.e., Screening) if the Principal Investigator (PI)  
determines that the benefit -risk profile for that individual study 
participant  is favorable .  The use of other investigational COVID 
vaccines that have  not received emergency, conditional, or standard 
market authorization and  are still only used in clinical studies will not 
be allowed at this time . 
19. Participation in the study would result in dona tion of blood in excess of [ADDRESS_371645] (whichever is 
longer) before signing of consent in any other clinical study involving an 
investigational study intervention or any other type of medical research.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 54 5.2.4.  Diagnostic Ass essments  
22. presence of HBsAg  or HBcAb  at screening:  
• Note: Evidence of HBV infection based on the results of test ing at 
Screening for HBsAg.  
• Patients who are negative for HBsAg should also be tested for anti -HBc, 
anti-HBs and HBV DNA and excluded according to the following 
algorithm:  
• Participants negative for anti -HBs but positive fo r anti-HBc (negative 
HBsAg status) and positive for HBV DNA are excluded.  
• Participants positive fo r anti-HBc (negative HBsAg status) and positive 
for anti -HBs (past and/or current evide nce) are immune to HBV and are 
not excluded.  
• Note: HBV DNA testing will only be performed during screening and 
prior to randomization  for participants with positive anti -Hbc and both 
negative HBsAg and anti -HBs (past and/or current evidence).  
23. Positive Hepa titis C antibody test result at Screening AND positive on reflex to 
Hepatitis C RNA.  
• Note: Participants with positive Hepatitis C antibody due to prior  
resolved disease can be enrolled only if a confirmatory negative 
Hepatitis  C RNA test is obtained (centr al lab will automatically reflex to 
HCV  RNA on positive HCVAb).  
24. Positive Hepatitis C RNA test result at Screening.  
• Note: Test is optional and participants with negative hepatitis C 
antibody  test are not required to also undergo hepatitis C RNA testing.  
25. Any Grade 3 -4 laboratory abnormality is exclusionary (with the exception of Grade 
3-4 CPK and lipid abnormalities (e.g. , total cholesterol, triglycerides, etc) following 
discussion and agreement by [CONTACT_37773]). A single repeat of any lab 
abnormal ity is allowed within a single Screening period to determine eligibility . 
26. Alanine aminotransferase (ALT) > 1.[ADDRESS_371646] and / or total bilirubin >1.5xULN 
(isolated bilirubin >1.5xULN is acceptable if total bilirubin is fractionated and direct 
bilirubin <35%).  A single repeat of ALT and / or bilirubin is allowed within a single 
Screening period to determine eligibility.  
27. Creatinine clearance (eGFR) of < 60 mL/min/1.73 m2 using  CKD -EPI [INVESTIGATOR_10908] 
(2021)  
28. Any acute laboratory abnormality at screen which, in the opi[INVESTIGATOR_163483], 
should preclude participation in the study of an investigational compound.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 55 5.2.5.  Other Exclusion Criteria  
29. Any positive result for illicit drug use (e.g., cocaine, heroin) at Screening. A positive 
screen for marijuana / THC is not exclusio nary.  
30. Heavy use of tobacco or nicotine containing products (≥ 20 cigarettes per day or 
equivalent, as determined by [CONTACT_093]).  
31. During the study, alcohol consumption will be limited to the following:  
• An average weekly intake of <14 drinks for males or <7 drink for females.  
One drink is equivalent to 12 g of alcohol: 12 ounces (360 mL) of beer, 5 
ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled 
spi[INVESTIGATOR_2120].  
5.3. Lifestyle considerations  
5.3.1.   and dietary restrictions   
• Participants will be required to fast for at least 8 hours (overnight) prior to the 
morning check -in for the Days 1, 2, 4, 7, 10, 17, 24, 31 and 38/Early Discontinuation 
Visits.  
• Blood work for the safety labs and HIV -1 RNA will  be drawn at the beginning of 
any clinic visit and, when applicable, before consumption of any meal and 
dosing.  See Section 1.3 (Schedule of Activities) and Section 8 (Study Assessments 
and Procedures) for order of assessments . 
• Refrain from excessive consumption of red wine, Seville oranges, grapefruit or 
grapefruit juice, pomelos, exotic citrus fruits, grapefruit hybrids, or fruit juices from 
[ADDRESS_371647] dose of study medica tion through the Day 10 visit. Excessive 
consumption is defined as more than 1 glass of red wine or juice or 1 fruit per day, in 
combination.   
5.3.2.  Alcohol  and tobacco  
• No alcohol consumption is allowed 8 hours prior to each blood collection for clinical 
laboratory tests and on intensive PK days  until after the final 
assessment of the day and release from the clinic.  Overall limitations on alcohol 
consumpt ion are described in S ection 5.2.5 .  
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 56 • Only clinically mild to moderate use (< 20 cigarettes per day or equivalent, as 
determined by [CONTACT_093]) of tobacco or nicotine containing products will be 
allowed during study participation, with extremely  limited use on the intensive PK 
days  to ensure it does not interfere with appropriate collection of 
samples , until after the final assessment of the day and release from the clinic.  
5.3.3.  Activity  
• Participants will abstain from strenuous exercis e for 48 hours before each blood 
collection for clinical laboratory tests. Participants may participate in light 
recreational activities during study participation . 
5.3.4.  Other restrictions  
Not applicable  
5.4. Screen failures  
A screen failure occurs when a participant who has consented to participate in the clinical 
study is not subsequently randomized to study intervention. A minimal set of screen 
failure information is required to ensure transparent reporting of screen failure 
participants to meet the CONS ORT publishing requirements and to respond to queries 
from regulatory authorities. Minimal information includes demography, screen failure 
details, eligibility criteria, information from any previous trials with the same IP, and any 
SAE.  
Individuals who do not meet the criteria for participation in this study (screen failure) 
may be rescreened. Screening assessments that yield abnormal results (e.g., a safety 
laboratory parameter) may be repeated once within the screening window at the 
discretion of the investigator. Individuals who failed initial screening but passed 
rescreening may be admitted into the study based upon clinical judgement with 
consultation with the ViiV medical monitor as necessary.  
Rescreened participants should be assign ed a new participant number for every 
screening/rescreening event. Previously assigned participant numbers are to be recorded 
in the participants’ CRF/eCRF. All screening procedures should be repeated at the 
rescreening visit.  
5.5. Criteria for temporarily dela ying 
enrollment/randomization/administration of study 
intervention  
Not applicable  
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 57 6. STUDY INTERVENTION(S ) AND CONCOMITANT 
THERAPY  
The definition of study intervention is provided in the table of definitions.  
6.1 Study intervention(s) administered  
Table 4 Study Intervention(s) Administered  
Intervention Label  VH4524184  Placebo to match VH4524184 
 
Intervention Name  [CONTACT_103701]4524184  Placebo to match VH4524184  
Intervention Description    
Type  Drug  Drug  
Dose Formulation    
Unit Dose Strength(s)   Not applicable  
Dosage Level(s)  Variable depending on dose  Variable depending on dose  
Route of Administration  Oral Oral 
Use Experimental  Placebo  
IMP and NIMP/AxMP.  IMP  IMP  
Sourcing  Provided centrally by [CONTACT_303824]4524184  Not applicable  
 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 58 Table 5 Study Arm(s ) 
1 The dose and frequency to be evaluated in Part 2 will be based on preliminary analyses of exposure and response data from Part 1. As a res ult, the arm description and the 
placebo to match in Part 2 would then be aligned to the specific dose that is chosen.Arm Title  VH4518424  
 Placebo for 
VH4524184  
 VH4518424  
 Placebo for 
VH4524184 
 VH4518424 
 Placebo for 
VH4524184 
 VH4518424  
 Placebo for 
VH4524184  
 
Part Part 1  Part 1  Part 1  Part 1  Part 1  Part 1  Part 2  Part 2  
Arm Type  Experimental  Placebo  Experimental  Placebo  Experimental  Placebo  Experimental  Placebo  
Regimen 
number  1 2 3 4 5 6 7 8 
Arm 
Description  
 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 59 6.2 Preparation, handling, storage, and accountability  
• The investigat or or designee must confirm appropriate conditions (e.g., temperature) 
have been maintained during transit for all study intervention received, and any 
discrepancies are reported and resolved before use of the study intervention.  
• Only participants enrolled  in the study may receive study intervention, and only 
authorized site staff may supply, prepare, or administer study intervention . 
• All study intervention must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in a ccordance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  
• The investigator, institution, the head of the medical institution (where applicable), 
or authorized site staff is responsible for study interv ention accountability, 
reconciliation, and record maintenance (i.e., receipt, reconciliation, and final 
disposition records).  
• Further guidance and information for the final disposition of unused study 
interventions are provided in the pharmacy manual.  
• Unde r normal conditions of handling and administration, study intervention is not 
expected to pose significant safety risks to site staff .  
• A MSDS/equivalent document describing occupational hazards and recommended 
handling precautions either will be provided to the investigator, where this is 
required by [CONTACT_1207], or is available upon request from [COMPANY_004].  
6.3 Assignment to study intervention  
All participants will be centrally assigned to randomized study intervention using an 
IWRS. Before the study is initiated, th e log -in information and directions for the IWRS 
will be provided to each site.  
Study intervention will be dispensed at the study visits as summarized in the SoA.  
Unused study intervention  may not be offered to the study 
particip ant beyond the expected dosing schedule as outlined in the SoA and may not be 
offered to any other person.  
6.4 Blinding, masking  
This is a double -blind (sponsor unblinded) placebo -controlled study in which participants  
and investigators are blinded to study in tervention at a participant level.  
The specific intervention to be taken by a participant will be assigned using an IWRS. 
The site will contact [CONTACT_303825] . 
 Potential bias will be reduced by [CONTACT_716]:  
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 60 6.4.1  Randomization and treatment assignment  
All participants will be randomized, according to the randomization schedule generated 
prior to the study by [CONTACT_303826]. Each participant scheduled to receive study drug will receive a treatment 
allocation number when randomized.  
Participants  and investigators will know to which double blinded arms (Cohorts 1, 2, 3 or 
4) participants are assigned to.  
The blind ing strategy for this study is further structured to ensure that no one at  VH/[COMPANY_004] 
who is involved in the management of individual participants is unblinded to treatment at 
the participant level. As a general principle during study conduct, members of the 
VH/[COMPANY_004] study team and other VH/[COMPANY_004] staff will remain blinded to the assignment for 
individual participants aside from where unblinding is necessary to support the informal 
planned interim analyses or becomes necessary for safety reasons.  
Refer to Section 9.[ADDRESS_371648] of 
the informal planned interim analyses.  
6.4.2  Central Laboratory  
The central  laboratory in charg e of HIV -1 RNA testing will be blinded to the study 
intervention assignment. Codes will be used to link the participant and study to each 
sample. There will be no link between the study intervention groups and the identity of 
the participant.  
The investiga tor, site staff and VH/[COMPANY_004] will be unblinded to HIV -1 RNA results 
performed at screening in order to determine HIV status for eligibility purposes.  
The investigator, site staff , and VH/[COMPANY_004] study team members involved in participant 
management , will be blinded to HIV -[ADDRESS_371649] of 
the informal planned interim analyses.  
6.4.3  Emergency unblinding  
The IWRS will be programmed with blind -breaking instructions. In case of an 
emergency, the investigator has the sole responsibility for determining if unblinding of a 
participants’ int ervention assignment is warranted. Participant safety must always be the 
first consideration in making such a determination. If the investigator decides that 
unblinding is warranted, the investigator may, at the investigator’s discretion, contact 
[CONTACT_103701]/[COMPANY_004] to  discuss the situation prior to unblinding a participant’s intervention 
assignment unless this could delay emergency treatment for the participant. If a 
participant’s intervention assignment is unblinded, VH/[COMPANY_004] must be notified 
CONFIDENTIAL  
 TMF-[ADDRESS_371650] the [COMPANY_004] helpdesk based 
on the information provided in the pharmacy manual. A physician other than the 
investigator (e.g., an  emergency room physician) or participant/participant’s caregiver or 
family member may also request emergency access to the participant’s study intervention 
information as per participant card.  
A participant may continue in the study if that participant’s intervention assignment is 
unblinded .  
VH/[COMPANY_004]’s Global Safety staff may unblind the intervention assignment for any 
participant with an SAE. If the SAE requires that an expedited regulatory report be sent 
to 1 or more regulatory agencies, a copy of the rep ort, identifying the participant’s 
intervention assignment, may be sent to investigators in accordance with local regulations 
and/or [COMPANY_004] policy.  
6.5 Study intervention compliance  
 
. The date and time of each dose 
administered  will be recorded in the source documents .  
6.6 Dose modification  
Modifications to the dose are not applicable in this study.   
6.7 Continued  access to study intervention after the end of the 
study  
Continued access to VH4524184 after the end of the study is not permitted since 
therapeutic benefit has not yet been established.   
Given the lack of longer -term clinical benefit (Section 2.3.2 ), ViiV Healthcare recognizes 
the balance between the need to conduct an early phase monotherapy clinical study (for 
the larger and long term unmet medical need) and the need for HIV -1 infected treatment 
naïve patients to receive ART as soon as possible after diagnosis. To meet both needs, 
this study design is efficient in screening (shortest period: approximately 7 to 14 days) 
and the monotherapy treatment with VH 4524184 (period: 10 days). On study Day 10,  
following the scheduled blood collection as per SoA, participants will commence 
standard -of-care ART  selected and prescribed by [CONTACT_303827].  
After  this time, the invest igator is responsible for ensuring that participants continue to 
receive  ART, whether or not the Sponsor is providing reimbursement for post -study 
treatment.  
CCI
CCI
CONFIDENTIAL  
 TMF-[ADDRESS_371651] the option (but are not required  if no 
access barrier ) to receive reimbursement from the Sponsor for locally marketed ARVs 
after the completion of the study  (i.e., Day 3 8 EOS which includes 10 days of double -
blind monotherapy and 28 days  of investigator chosen SOC ) for up to a maximum of [ADDRESS_371652]  of 
care.  
6.8 Treatment of overdose  
An overdose is any dose of study intervention given to a participant that exceeds the 
planned, randomized dose for an individual within a given dose group.  
In the event of an overdose, the investigator should:  
1. Evalu ate the participant to determine, in consultation with the medical monitor, if 
possible, whether study intervention should be interrupted or whether the dose 
should be reduced.  
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities unt il 
VH4524184 can no longer be detected systemically  as medically 
appropriate.  
3. Obtain a plasma sample for PK analysis if requested by [CONTACT_71908] 
(determined on a case -by-case basis).  
4. Document the quantity of the excess dose as w ell as the duration of the overdose.  
6.9 Prior and concomitant therapy  
Concomitant medications (prescription and non -prescription) should be administered 
only as medically necessary during the study. Chemoprophylaxis for HIV -associated 
conditions is encouraged , if appropriate, at the discretion of the participant and their 
physician.  
Because vaccines may cause a temporary increase in the level of HIV -[ADDRESS_371653] 14 days prior to 
Screeni ng (if an experimental vaccine, within at least [ADDRESS_371654] dose). Please 
discuss with medical monitor if planning to give vaccines during this time.  
Any medication or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrolment or receives during the study must be recorded along with:  
• Reason for use  
• Dates of administration including start and end dates  
• Dosage information including dose and frequency  
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 63 The VH medical monitor should be contact[CONTACT_61519].  
6.9.1  Permitted Medications  
1. Acetaminophen/paracetamol at doses of ≤2 g/day or NSAIDs are permitted for use 
any time during the study and their  use documented in the CRF.  
2. In the event of irritation from ECG leads, up to 2.5% topi[INVESTIGATOR_303780] . 
3.  Other concomitant medications may be considered on a case -by-case basis by [CONTACT_303828].  
4. Participants must notify their Investigator of any current or proposed concomitant 
medication, whether prescribed or over -the counter because of the potential for 
interactions between such treatments and the s tudy medications.  
6.9.2  Prohibited Medications  
See Section 5.2.2 . 
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 64 7 DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL  
7.1 Discontinuation of study intervention  
‘Discontinuation’ of study intervention refers to any participant who has not received all 
planned doses of  the study intervention.  In rare instances, it may be necessary for a 
participant to permanently discontinue study intervention.  
If study intervention is permanently discontinued, the participant should remain in the 
study, continue to comply with all other aspects of the protocol (such as starting the first 
dose of standard of care ART on Day 10) and be followed according to the So A (Section 
1.3) to the EOS  as defined in the protocol . 
If participants prematurely discontinue study treatment prior to Day 1 0 (primary 
endpoint), participants may be replaced at the discretion of the Sponsor in consultation 
with the investigator.  
Participants will not be replaced if the reason for discontinuation from the study 
treatment is due to a safety concern which the investigator considers reasonably 
attributable to study treatment e.g., when a participant meets stoppi[INVESTIGATOR_3418]. Refer to 
Section 7.1.2  (Liver chemistry stoppi[INVESTIGATOR_3418]), Section 7.1.3  (QTc st oppi[INVESTIGATOR_3418]) 
and Section 7.1.5  (Suicidal ideation and behavior ) and Section 7.1.6  (Hypersensitivity 
reactions).  
A participant may be discontinued from the study intervention at any time  if any of the 
protocol individual stoppi[INVESTIGATOR_23893] :  
• Emergence of any positive (abnormal)  CSSRS response , or participant report of 
suicidal ideation and behavior at any time during the study,  confirmed by [CONTACT_92685] a clinician (or qualified designee) during the monotherapy  period . 
• Pregnancy  
• ≥ Grade 3 AE (or  clinically significant laboratory abnormality) suspected to be 
related to VH4524184 . 
• An SAE, regardless of its severity, that is considered to be clinically significant 
and reasonably attributable to dosing with VH4524184, in the opi[INVESTIGATOR_684].   
• A grade ≥2 rash with concurrent fever with or without concur rent elevations in 
liver biochemistry reasonably attributable to dosing with VH4524184, in the 
opi[INVESTIGATOR_689].   
• Emergent medical condition that is judged by [CONTACT_303829]’s safety if he or she continues to rece ive the study drug . 
CONFIDENTIAL  
 TMF-17008580  
 218806  
 65 • Termination of the study by [CONTACT_1034]. Safety data will be reviewed by [CONTACT_303830]. If a safety concern arises, a 
decision about continuation of the study will be made.  
• Loss of ability to free ly provide consent due to incarceration or involuntary 
treatment of either a psychiatric or physical (e.g., infectious disease) illness . 
• Repeat non -adherence by [CONTACT_303831] (as determined by [CONTACT_303832])  
• Clinical criteria for stoppi[INVESTIGATOR_303781] ( as outlined below in Section 7.1) 
7.1.[ADDRESS_371655] below:  
Reasons  Additional items/Sub -reasons  
AE  
Lack of efficacy   
Lost to follow -up Subject Relocated  
Subject was Incarcerated  
Other, specify  
Unknown  
Participant Reached Protocol -Defined 
Stoppi[INVESTIGATOR_303782] -19 Pandemic  
Other  
Other  Specify  
Death   
 
  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 66 7.1.2  Liver chemistry stoppi[INVESTIGATOR_303783] a participant  if liver chemistry stoppi[INVESTIGATOR_118048]:  
Liver Chemistry Stoppi[INVESTIGATOR_2121] – Liver Stoppi[INVESTIGATOR_303784]: ALT = alanine transaminase; INR = international normalized ratio; SAE = serious adverse event; 
ULN = upper limit of normal.  
Refer to Section 10.[ADDRESS_371656] of the participant.  
Refer to Section  8.3.7  for information about study pausing criteria.   
7.1.3  QTc Stoppi[INVESTIGATOR_303785] (QTcF) formula will be used in the study.  
• A participant that meets either bulleted criterion based on ECG readings will be 
withdrawn from study treatment.  
• QTcF >500 msec,  
• Change from baseline:   QTcF>60 msec  
• The QTcF must  be used for each individual participant  to determine eligibility for , 
and disco ntinuation from , the study. This formula may not be changed or substituted 
once the participant has been enrolled.  

CONFIDENTIAL  
 TMF-17008580  
 218806  
 67 • The QTcF stoppi[INVESTIGATOR_303786] a brief (e.g., 5 -10 minute) recording period.   
If a clinically significant finding is identified (including, but not limited to, changes from 
baseli ne in in QTcF >60 msec ) after enrollment, the investigator or qualified designee 
will determine if any change in participant management is needed. This review of the 
ECG printed at the time of collection must be documented. Any new clinically relevant 
finding should be reported as an AE.  
7.1.4  Pregnancy  
Participants who become pregnant during the study should discontinue study drug. Refer 
to Section 8.4.5  for reporting requirements.  
7.1.5  Suicidal ideation and behavior  
Participants who experience a confirmed positive eCSSRS , or who report suicidal 
ideation and /or behavior at any time during the study,  should have study drug withdrawn 
and should be referred for further medical assessment and treatment as appropriate. The 
participant should be encouraged to continue in the study and be followed as per the SoA 
(See Section 1.3)   
See Section 8.3.6 , Suicidal ideation and behavior risk monitoring, for additional 
guidance.  
7.1.6  Hypersensitivity reactions Stoppi[INVESTIGATOR_303787] ≥[ADDRESS_371657] the Investigator immediately if 
there is any worsening of symptoms or if f urther systemic signs or symptoms develop. 
Antihistamines, topi[INVESTIGATOR_11930], or antipruritic agents may be prescribed.  
7.1.7  Temporary discontinuation  
Temporary discontinuation of VH4524184/placebo is not allowed in this study.  
7.1.8  Rechallenge  
Rechallenge with VH4524184/placebo is not allowed in this study.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 68 [IP_ADDRESS]  Study Intervention Restart or Rechallenge After Liver Stoppi[INVESTIGATOR_303788].  
7.2 Participant discontinuation/withdrawal from the study  
A participant may withdraw from the study at any time at the participant’s own request 
for any reason (or without providing any reason).   
A participant may be withdrawn  from the study  at any time at the discretion of the 
investigator for safety, behavioral, or adherence reasons.  Discontinuing from the study 
for safety reasons should be infrequent.  
As described in Section  7.1, participants who meet a safety stoppi[INVESTIGATOR_303789] a safety reason, should remain in the study, 
continue to comply with all other aspects of the protocol (such as starting the fir st dose of 
standard of care ART on Day 10) and be followed according to the SoA (Section  1.3) to 
the EOS as defined in the protocol.  
Participants will not be replaced if the reason for discontinuation from the study is due to 
a safety concern.  
If particip ants prematurely discontinue the study for non -safety reasons prior to Day 10 
(primary endpoint), additional replacement participants may be enrolled at the discretion 
of the sponsor and investigator. These replacement participants will be assigned to the 
same treatment sequence and same dose as the corresponding participant who 
prematurely discontinued from the study.   
Investigators will attempt to contact [CONTACT_103706] -up. 
At the time of discontinuing from t he study, if possible, an early discontinuation visit 
should be conducted, as shown in the SoA. See SoA for data to be collected at the time of 
study discontinuation and follow -up and for any further evaluations that need to be 
completed.  The participant w ill be permanently discontinued from the study intervention 
and the study at that time.  
All data and samples collected up to and including the date of withdrawal of/last contact 
[CONTACT_103707]. If the participan t withdraws 
consent for disclosure of future information, the sponsor may retain and continue to use 
any data collected before such a withdrawal of consent.  
If a participant withdraws from the study, the participant may request destruction of any 
samples t aken and not tested, and the investigator must document this in the site study 
records.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 69 The primary reason for participant discontinuation/ withdrawal from the study will be 
documented in the eCRF  based on the list below:   
Reasons  Additional items/Sub -reasons 
AE  
Lack of efficacy   
Lost to follow -up Subject Relocated  
Subject was Incarcerated  
Other, specify  
Unknown  
Participant Reached Protocol -Defined 
Stoppi[INVESTIGATOR_303790] -19 Pandemic  
Other  
Other  Specify  
Death   
 
Participants who are withdrawn from the study because of AEs/SAEs must be clearly 
distinguished from participants who are withdrawn for other reasons. Investigator will 
follow participants who are withdrawn from the study due to an AE/SAE until the event 
is resolved (see Section [IP_ADDRESS] ). 
7.[ADDRESS_371658] be taken if a participant fails to return to the clinic for a 
required stud y visit:  
• The site must attempt to contact [CONTACT_14315], counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether the participant wishes to and/or shoul d 
continue in the study.  
• Before a participant is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls, and if necessary, a certified letter to the participan t’s last known mailing 
CONFIDENTIAL  
 TMF-17008580  
 218806  
 70 address or local equivalent methods). These contact [CONTACT_14316]’s medical record.  
• Should the participant continue to be unreachable, the participant will be considered 
to have withdrawn from the s tudy.  
• Site personnel, or an independent third party, will attempt to collect the vital status of 
the participant within legal and ethical boundaries for all participants randomized, 
including those who did not get study intervention. Public sources may be  searched 
for vital status information. If vital status of the participant is determined as deceased, 
this will be documented and the participant will not be considered lost to follow -up. 
Sponsor personnel will not be involved in any attempts to collect vi tal status 
information.  
8 STUDY ASSESSMENTS AND PROCEDURES  
• Study procedures and their timing are summarized in Section  1.3. Protocol  waivers or 
exemptions are not all owed.  
• Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criter ia. Subjects who have signed informed consent 
but are not eligible to proceed should be recorded in the eCRF with a status of ‘screen 
failure’.  
• Procedures conducted as part of the participant’s routine clinical management (e.g., 
blood count ) and obtained b efore signing of the ICF may be utilized for screening or 
baseline purposes provided the procedures met the protocol -specified criteria and 
were performed within the timeframe defined in the SoA.  
• In the event of a significant study -continuity issue (e.g., caused by a pandemic), 
alternate strategies for participant visits, assessments, study intervention distribution 
and monitoring may be implemented by [CONTACT_103708], as per local 
health authority/ethics requirements.   
• Safety/laboratory/analyte results (e.g., HIV RNA (viral loads) that could unblind the 
study will not be reported to investigative sites or other blinded personnel until the 
study has been unblinded.  
• The maximum amoun t of blood collected from each participant over the duration of 
the study or any 56 day period while enrolled in the study, including any extra 
assessments that may be required, will not exceed 500 mL.  
• Repeat or unscheduled samples may be taken for safety reasons or for technical issues 
with the samples.  
• Pharmacokinetic results that could unblind the study will not be reported to 
investigative sites or other blinded personnel.  
• Order of assessments:  Assessment procedures should occur in the following order:  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 71 1. ECG  (if applicable)  
2. Vital sign assessment  
3. CSSRS  
4. Blood draw s; (HIV RNA to be collected at same time as pre -dose PK 
sample [with no preference as to which is drawn first ]) 
5.   
•  All Day [ADDRESS_371659] demographic data such as year of birth, sex at birth, current sex, cur rent gender 
identity, race, and ethnicity in the participant’s eCRF.  
Collection of these demographic data is necessary to assess and monitor the diversity of 
the trial participants , and to determine if the trial participants  are truly representative  of 
the impacted population.  
8.1.2  Medical/ vaccination history  
Obtain the participant’s medical and disease history by [CONTACT_103709]/or review of the participant’s medical records. Record any pre -existing conditions 
(including reasons for taking con comitant medications), signs and/or symptoms present 
prior to  the first dose of study intervention in the eCRF.  
8.2 Efficacy assessments  
Planned timepoints for all efficacy assessments are provided in the SoA  (Section 1.3). 
8.2.1  Quantitative HIV -1 RNA  
Plasma for quantitative HIV -1 RNA will be collected at timepoints listed in Section  1.3. 
An HIV -1 RNA PCR assay (Cobas HIV -1) with a linear range of 20 to 10,000,000 
copi[INVESTIGATOR_014]/mL will be used. Details concerning the handling, labeling and shippi[INVESTIGATOR_303791].   
8.2.[ADDRESS_371660] of Clinical Laborator ies and Key Vendors 
document for laboratory names and addresses of the clinical laboratories used in this 
study.   
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 72 8.3 Safety assessments  
Planned timepoints for all safety assessments are provided in the SoA.  
8.3.1  Physical examination/history directed physical exami nation  
• A complete physical examination will include, at a minimum, assessments of the 
skin, cardiovascular, respi[INVESTIGATOR_696], gastrointestinal, and neurological systems.  
• A brief physical examination will include, at a minimum, assessments of the skin, 
lungs, ca rdiovascular system, and abdomen (liver and spleen).  At the discretion of the 
investigator, a brief physical examination may be made a complete physical 
examination.  
• Investigators should pay special attention to clinical signs related to previous serious 
illnesses.  
• Height and weight measurements will be used to calculate BMI .  
8.3.2  Vital signs  
• Body temperature, pulse rate, respi[INVESTIGATOR_697], and blood pressure will be recorded 
(before blood collection for laboratory tests).  
• Body temperature will be assessed as per site’s standard practice and should be 
measured at the same location throughout the study.  
• Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_371661] for the participant in a quiet setting without distractions. Blood pressure and 
pulse measurements will be assessed in a semi -supi[INVESTIGATOR_103645] a completely 
automated device. Manual techniques will be used only if an automated device is not 
available.  
• If abnormalities in pulse or blo od pressure are noted, repeat recordings should be 
measured in triplicate, at least 1 minute apart. The average of the 3 readings will be 
recorded in the eCRF.   
8.3.3  Electrocardiograms  
• 12-lead ECG(s) will be obtained as outlined in the SoA (see Section 1.3) using an 
ECG machine that automatically calculates the heart rate and measures PR, QRS, 
QT, and [QTc] intervals. Each ECG recording will be obtained after the partici pant 
has been in a semi -supi[INVESTIGATOR_21683] [ADDRESS_371662] the VH medical monitor with any concerns.  
• If clinically indicated,  the ECG should be repeated twice more (triplicate obtained) 
with recordings obtained as closely as possible in succession. Data from the average 
of 3 ECGs will be used for any action taken. Triplicate ECGs should be obtained if 
the investigator determines an ECG abnormality is clinically significant or if the 
investigator is unable to dete rmine the significance of abnormalities relating to rate, 
rhythm, or intervals (including prolongation of the QT interval),   
• Refer to Section  7.1.3  for QTc stoppi[INVESTIGATOR_303792].   
CONFIDENTIAL  
 TMF-17008580  
 218806  
 73 8.3.4  Clinical safety laboratory tests  
• See Section 10.[ADDRESS_371663] of clinical laboratory tests to be performed in accordance 
with lab manual and the SoA (Section 1.3). 
• The investigator must review the laboratory results, document this review, and 
record any clinically sign ificant changes occurring during the study as an AE. The 
laboratory results must be retained with source documents.  
• Abnormal laboratory findings associated with the underlying disease are not 
considered clinically significant unless judged by [CONTACT_303833]’s condition . 
• All laboratory tests with values considered clinically significantly abnormal from  
dosing of the study intervention until EoS visit (i.e. , Day 38) should be repeated until 
the values ret urn to normal or baseline or are no longer considered clinically 
significant by [CONTACT_10982].  
- In the absence of a diagnosis, abnormal laboratory findings 
assessments or other abnormal results the investigator considers 
clinically sig nificant will be recorded as an AE or SAE, if they meet 
the definition of  an AE or SAE (refer to Section  10.3.1  and Section 
10.3.2 ).  
- If clinically significant values do not return to normal/baseli ne within 
a period of time judged reasonable by [CONTACT_093], the etiology 
should be identified, and the sponsor notified.  
- If laboratory values from non -protocol -specified laboratory tests 
performed at the institution’s local laboratory require a chang e in 
participant management or are considered clinically significant by [CONTACT_1275] (e.g, SAE or AE), then the results must be recorded.  
8.3.5  Pregnancy testing  for participants of childbearing potential  
• Refer to Section 5.1 Inclusion Criteria for pregnancy testing entry criteria.  
• Refer to Section 1.3 (Schedule of Activities) for pregnancy testing schedule.  
• POCBP  must perform a pregnancy test before the administration of any dose of 
study intervention during the Monotherapy Period. Pregnan cy testing will continue 
throughout the Follow -up Period.  
• Serum samples will be sent for pregnancy testing for the Screening Visit. At the Day 
1 Visit (before start of study treatment), a urine test must be used to confirm 
pregnancy status prior to admini stration of study treatment.  
• Pregnancy testing must be done even if the participant is menstruating at the time of 
the study visit. The study intervention may only be administered if the pregnancy test 
is negative.  
• Additional serum or urine pregnancy tests  may be performed, as determined 
necessary by [CONTACT_31837], to establish the absence 
of pregnancy at any time during the participant’s participation in the study.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 74 • Refer to Section 8.4.5  (Pregnancy  reporting ) for pregnancy reporting requirements 
and information on study continuation for participants who become pregnant during 
the study.  
8.3.6  Suicidal ideation and behavio r risk monitoring  
Although VH4524184 is not being developed for a neurologic or psychiatric condition, 
participants will be excluded based on any pre -existing psychiatric condition (including 
assessment using the CSSRS). Depression (including suicidal ideation and behaviors , 
particularly in patients with a pre -existing history of depression or psychiatric illness) are 
adverse drug reactions .  
Participants receiving VH4524184 should be monitored appropriately and observed 
closely for SIB or any other unusu al changes in behavior. Participants who experience 
signs of SIB should undergo a risk assessment. All factors contributing to SIB should be 
evaluated and the participant should not receive any additional doses of VH4524184.  
Assessment of suicidal ideatio n and behavior / intervention emergent suicidal ideation 
and behavior will be monitored using the electronic CSSRS (see SoA, Section 1.3 for 
details) at Screening, on Day 10 and the final follow -up visit, as well as at early 
termination, if applicable.  As described in Section  7.1, any positive (abnormal) CSSRS 
response indicating SIB , or SIB reported by [CONTACT_303834], will result in withdrawal of study drug. In either case (screening or post -dose) of 
positive (abnormal) response confirmed by [CONTACT_093], the PI/SI will arrange for 
urgent specialist psychiatric evaluation and management.  
The definitions of behavioral suicidal events used in this scale are based on those used in 
the Columbia Suicid e History Form [ Posner , 2007]. Questions are asked on suicidal 
behavior, suicidal ideation, and intensity of ideation. Screening visit questions will be in 
relation to lifet ime experiences and current experiences (within the past 2 months) and all 
subsequent questioning in relation to the last assessment. A response graded as level 4 or 
5 for suicidal ideation and/or any positive response to questions addressing suicidal 
beha vior is considered a positive CSSRS which then should be confirmed by [CONTACT_303835].  
Participants who experience a confirmed positive CSSRS , or who report SIB at any other 
time during the study , should have study drug withdrawn  and should be referred for 
further medical assessment and treatment as appropriate. The participant should be 
encouraged to continue in the study and be followed as per the SoA.  (See Section 1.3).   
Additionally, the investigator will collect information using the PSRAE eCRF form in 
addition to the AE (non -serious or SAE) eCRF form on any subject that experiences a 
possible suicida lity-related AE while participating in this study. This may include, but is 
not limited to, an event that involves suicidal ideation, a preparatory act toward imminent 
suicidal behavior, a suicide attempt, or a completed suicide. The investigator will 
exercise his or her medical and scientific judgment in deciding whether an event is 
possibly suicide related. PSRAE forms should be completed and reported to V H/[COMPANY_004] 
within 1 week of the investigator diagnosing a possible suicidality -related AE.  
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 75 8.3.7  Study pausing r ules 
Participant  safety will be continuously monitored by [CONTACT_1689], designated 
Safety Lead (or delegate) , throughout the study.  Pertinent findings and conclusions are 
shared with the product’s SRT for review of the overall benefit -risk profile o f the 
product. The Sponsor’s governance group, VSLC will review data and the team’s 
recommendation when any pausing/stoppi[INVESTIGATOR_26501].  The VSLC is comprised of 
senior representatives from various departments, including clinical development, safety, 
toxicology, pharmacovigilance, epi[INVESTIGATOR_623], and medical affairs.  The VSLC will 
govern whether enrollment may be resumed/modified, a given treatment arm will be 
stopped, or the study stopped. (See Section 10.1.6  for more details on VSLC)  
The following study pausing criteria would be applied:   
• Death of a participant, regardless of investigator ’s assessment of causality  
• Any Grade 4 event or an SAE, regardless of its severity, that is considered to be 
clinically significant and reasonably attributable to dosing with VH4524184 in the 
opi[INVESTIGATOR_303793].   
• Any Grade 3 or higher AE (of the same type) in 2 or more participants , leading to 
the decisio n to withdraw from the study  (by [CONTACT_093] ), assessed  by [CONTACT_303836]4524184 .  
• Any Grade 2 or higher rash with evidence of systemic involvement (e.g., fever, 
liver transaminase elevation and/or eosinophilia)  that the investigator considers 
reasonably attributable to VH4524184  occurring in two or more participants .  
• Any Grade 4 laboratory abnormality  (of the same type)  or Grade 3 laboratory 
abnormalities ( of the same type, with the exception of an asymptomatic  Grad e 4 
lipid abnormalities or CPK increase) that the investigator considers reasonably 
attributable to VH4524184 , in two or more participants .  
• Any participant meeting liver stoppi[INVESTIGATOR_303794]452418 4.  
• Any participant meeting QTc stoppi[INVESTIGATOR_303794]4524184.   
• Clinically significant arrhythmia in two or more participants.  
8.4 Adverse Events (AEs) serious adverse events (SAEs), and other 
safety rep orting  
For definitions relating to safety information see Section 10.3 
The investigator and any qualified designees are responsible for detecting, documenting, 
and recording events that meet the definition of an AE or SAE and remain responsible for 
following up AEs that are serious, considered related to the study intervention or study 
procedures, or that caused the participant to discontinue the study intervention o r study 
(see Section 7). This includes events reported by [CONTACT_2299] (or, when appropriate, by 
a caregiver, surrogate, or the participant’s legally authorized representative).  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 76 The method of recording, evaluating, and assessing causality of AEs and SAEs and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3 
(AEs and SAEs: Definitions and procedures for recording, evaluating, follow -up, and 
reporting), and/or Section 10.6 (Divisi on of AIDS Table for Grading the Severity of 
Adult and Pediatric Adverse Events) . 
8.4.1  Time period and frequency for collecting AEs and SAEs  
All SAEs will be collected from the signing of the ICF until the final follow -up visit.  
Medical occurrences that begin before the start of study intervention but after obtaining 
informed consent will be recorded as medical history/current medical conditions, not as 
AEs.  
All SAEs will be recorded and reported to the sponsor or designee immediately and under 
no circumstance should this exceed 24 hours, as indicated in Section 10.3 and/or Section 
10.7. The investigator will submit any updated SAE data to the sponsor within [ADDRESS_371664]  study AE/SAE is defined as any event that occurs outside of the AE/SAE 
reporting period defined in Section 10.3.[ADDRESS_371665] 
promptly notify the sponsor . 
8.4.2  Method of detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and SAEs. Open -ended and 
nonleading verbal questioning of the participa nt is the preferred method to inquire about 
AE occurrences.  
8.4.3  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs  will be followed until resolu tion, 
stabilization, the event is otherwise explained, or the participant is lost to follow -up (as 
defined in Section 7.3). Further information on follow -up proced ures is provided in 
Section [IP_ADDRESS] . 
8.4.4  Regulatory reporting requirements for SAEs  
• Prompt notification by [CONTACT_303837]-17008580  
 218806  
 77 safety of a study intervention under clinical investigation are met. See Section  8.4.1  
for reporting timeframes.  
• For SAEs,  the investigator must always provide an assessment of causality at the 
time of the initial report, as defined in the Section [IP_ADDRESS] . 
• An investigator who receives an investigator safety report describing an SAE or 
other specific safety information (e.g., summary or listing of SAEs) from the sponsor 
will review and then fil e it along with the IB and will notify the IRB/IEC, if 
appropriate according to local requirements.  
• Investigator safety reports must be prepared for S[LOCATION_003]Rs according to local 
regulatory requirements and sponsor policy and forwarded to investigators as 
necessary.  
8.4.[ADDRESS_371666] not receive 
subsequent doses of the study intervention but may continue other study procedures at the 
discretion of the investigator.  
• Details of all pr egnancies in female participants will be collected after the start of 
study treatment in the Monotherapy Period (Day 1) and until the final visit in the 
Follow -up Period (Day 38). Report all pregnancies to the Medical Monitor.  
• If a pregnancy is reported, t he investigator will record pregnancy information on the 
appropriate form (initial notification form or pregnancy follow -up form) and submit 
it to the sponsor within 24 hours of learning of the female participant’s pregnancy 
(see Section 10.3.7 ). 
• Any pregnancy complication or elective termination of a pregnancy for medical 
reasons will be reported as an AE or SAE.  
• Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs and will be reported 
as such.  
• The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up in formation on the participant and the neonate and 
the information will be forwarded to the sponsor. See  Section  10.3.7  for reporting 
timeframes.  
• Any poststudy pregnancy -related SAE considered reasonably related to the study 
intervention by [CONTACT_79982] 8.4.4 . While the investigator is not obligated to actively seek this information 
in former study participants, he or she may learn of an SAE through spontaneous 
reporting.  
• All investigators are strongly encouraged to report all pregnancies  exposed to 
standard of care ART to the Antiretroviral Pregnancy Registry (APR) as soon as the 
pregnancy is identified. Pregnancies can be reported to the Registry at 
[EMAIL_5954] via the data forms available at www.APRegistry.com.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 78 8.4.6  Cardiovascular  events  and death events  
For any CV events detailed in Appendix Section 10.3.4  and all deaths, whether or not 
they are considered SAEs, specific CV and Death sectio ns of the eCRF will be required 
to be completed. These sections include questions regarding CV (including sudden 
cardiac death) and non -CV death.  
The CV eCRFs are presented as queries in response to reporting of certain CV MedDRA 
terms. The CV information  should be recorded in the specific CV section of the eCRF 
within [ADDRESS_371667] be completed within  1 week 
of when the death is reported.  
8.4.7  Disease -related events and/or disease -related outcomes not 
qualifying as AEs or SAEs  
The events or outcomes listed in the CDC Classification System for HIV -1 Infections 
(Section  10.7) will be recorded on the HIV -Associated Conditions eCRF page if they 
occur. However, these individual events or outcomes, as well as any sign, symptom, 
diagnosis, illness, and/or clinical laboratory abnormality that can be linked to any of these 
events or  outcomes are not reported to VH/[COMPANY_004] as AEs and SAEs even though such 
event or outcome may meet the definition of an AE or SAE, unless the following 
conditions apply : 
• The investigator determines that the event or outcome qualifies as an SAE under 
part ‘f’ of the SAE definiti on (Section  10.3.2 ), or 
• The event or outcome is in the investigator’s opi[INVESTIGATOR_103650], 
frequency or duration than expected for the individual participant, or  
• The investigator considers that there is a reasonable possibility that the event was 
related to study intervention.  
• Death occurring for any reason during a study, including death due to a disease -
related event, will always be rep orted promptly, or  
• Lymphomas and invasive cervical carcinomas are excluded from this exemption; 
they must be reported as SAEs even if they are considered to be HIV -related.  
• If any of the above conditions are met then record the DRE on the SAE page 
rather than the HIV Associated Conditions eCRF.  
CONFIDENTIAL  
 TMF-[ADDRESS_371668]-gcsp-ctsm -[EMAIL_2034]   
Available 24/24 hours and 7/[ADDRESS_371669]  
The investigator (or designee) must provide the participant/participant’s LAR(s) with a 
“participant card” containing information about the clinical study. The 
participant/participant’s LAR(s) must be instructed to always keep the participant card in 
their possession for the duration of the study. In an emergency, this card serves to inform 
the responsible attending physician/LAR/caregiver/family member  that the participant is 
in a clinical study and that relevant information may be obtained by [CONTACT_103715](s) or their back up.  
8.5 Pharmacokinetics  
• Intensive and single PK sampling is pre -specified as per the SoA (Section  1.3). 
• Otherwise on single PK draw days  a single PK sample will be 
drawn in conjunction with the study visit and as close to an every [ADDRESS_371670] 
dose cycle as possible.  
• Collected PK sa mples may not be analyzed if concentrations below the limit of 
quantification were previously achieved or if the participant was assigned to placebo.  
• Refer to Table 7 for the permissible windows , dosing and PK draws for 
intensive PK days.  
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 80 Table 7 Intensive Pharmacokinetic Sampling  
 Time of Event  Window  Time Relative to Dosing  
Hour:Minute  
Dosing 
Day  Not 
applicable  
Pre-dose PK collection  Not 
applicable  Collect pre -dose sample prior to dosing. There 
is allowance to collect the sample earlier and 
up to 90 minutes prior to dosing  
Administer study treatment and start 
the clock for subsequent blood 
draws.  Not 
applicable  00:00  
• Instructions for the collection and handling of biological samples will be provided by 
[CONTACT_303838] . 
- Blood samples of approximately 2 mL  will be collected and processed to 
plasma for measurement of plasma concentrations of study intervention.  
- The actual date and time (24 -hour clock time) of each sample will be 
recorded.  
- Samples to be stored in an upright position at -70°C or colder until 
shipment to the test laboratory. Refer to the List of Clinical Laboratories 
and Key Vendors document for laboratory names and addresses of the 
clinical laboratories used in this study.  
• A maximum of 2 mL samples may be collected at additi onal timepoints during the 
study if warranted and agreed upon between the Investigator and the sponsor. The 
timing of sampling may be altered during the study based on newly available data 
(e.g., to obtain data closer to the time of peak plasma conce ntrations) to ensure 
appropriate monitoring.  
• Plasma samples will be used to evaluate the PK concentrations of VH4524184 and 
may also be used to evaluate safety or efficacy aspects related to concerns arising 
during or after the study.  
• Intervention concent ration information that would unblind the study will not be 
reported to investigative sites or blinded personnel until the study has been unblinded.  
CCI
CCI
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 81 8.6 Pharmacodynamics  
See Section  8.2 and Section  8.5 for relevant efficacy and PK assessments.  
8.7 Genetics  
Genetics are not evaluated in this study.  
8.8 Biomarkers  
Plasma samples for exploratory resistance testing will be collected according to the 
schedule described in Section 1.3 and as detailed in the Laboratory Manual. 
Resistance results will not be available in time to inform the treatment management 
of participants during the study. Samples from Day 1 (pre -dose) and Day 10 will be 
batch tested for viral genotypic and phenotypi c on treatment changes and/or 
resistance to the  using the Monogram Biosciences Inc. based assays. Plasma 
from additional timepoints may be assayed if needed.  
Additional blood samples may be drawn for local genotypic/phenotypic analysis, 
according to  local guidelines. These tests are optional and will be conducted in 
accordance with local guidelines for the management of HIV -[ADDRESS_371671] of care ART. Locally obtained 
genotypic/phenotypic re sults will be retained in the participant’s medical record at 
the site and will not be transferred to VH/[COMPANY_004].  
VH/[COMPANY_004] may store samples for up to 20 years after the end of the study to achieve 
study objectives. Additionally, with participants’ consent, samp les may be used for 
further research by [CONTACT_103701]/[COMPANY_004] or others such as universities or other companies to 
contribute to the understanding of HIV -1 or other diseases, the development of 
related or new treatments, or research methods.  
8.9 Immunogenicity assessments  
Immunogenicity is not evaluated in this study.   
8.10 Health economics or medical resource utilization and health 
economics  
Health economics OR Medical resource utilization and health economics parameters are 
not evaluated in this study.  
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 82 9 STATISTICAL CONSIDERATIONS  
The statistical analysis plan (SAP) will be finalized prior to database lock and it will 
include a more technical and detailed description of the statistical analyses described in 
this section. This section is a summary of the planned statistical analyses  of the most 
important endpoints including primary and key secondary endpoints. If methods in the 
SAP differ from the methods described in the protocol, the SAP will be followed.  
9.1 Statistical hypotheses  
The primary objective will be addressed using an estim ation approach (descriptive 
statistics) with no hypothesis testing. The primary treatment effect to be estimated is the 
maximum change from baseline in plasma HIV -1 RNA over the monotherapy period.  
9.2 Analysis sets  
Analysis Set  Definition / Criteria  Analyses  Evaluated  
Screened  • All participants who were screened for eligibility.  • Study Population  
Randomized  • All participants who were randomly assigned to study 
intervention in the study.  
• The screened, enrolled and randomized populations must 
be nested, i.e. the enrolled population must be a subset of 
the screened population, the randomized population must 
be a subset of the enrolled population.  • Study Population  
Safety  • All participants who received at least 1 partial or full dose of 
study intervention.  
• Partic ipants will be analyzed according to the study 
intervention they actually received.  • Safety  
Full Analysis Set 
(FAS)  • All randomized participants who received at least 1 full dose 
of study intervention.  
• Data will be reported according to the randomized study 
intervention.  • Efficacy  
Per-protocol (PP)  • All participants in the FAS for whom there were no major 
protocol deviations that impact the primary analyses.  
• Data will be reported according to the study intervention 
actually received.  
• Specific details of major protocol deviations that would 
exclude participants from the PP analysis set will be 
provided in the SAP.  • Efficacy  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 83 Analysis Set  Definition / Criteria  Analyses  Evaluated  
Pharmacokinetic 
(PK) • All participants in the Safety analysis set who had at least 1 
non-missing PK assessment (Non -quantifiable [NQ] values 
will be considered as non -missing values).  
• Data will be reported according to the actual study 
intervention.  • PK 
9.3 Statistical analyses  
9.3.1  General considerations/definitions  
Data will be summarized by [CONTACT_303839] , unless otherwise specified.  
Data will be summarized either by [CONTACT_303840] s eparately for the monotherapy period and 
overall (i.e., monotherapy period plus SOC period), as appropriate for each endpoint, 
unless otherwise specified .  
For all endpoints, the baseline value will be  the latest pre -dose assessment with a non -
missing value, including those from unscheduled visits.  
Continuous and categorical variables will be summarized using the following descriptive 
statistics, unless otherwise specified:  
• Continuous data: n (number of  participants used for the summary), arithmetic mean, 
SD, median, interquartile range, minimum and maximum. For PK data, geometric 
mean, SD of log -transformed data and geometric %CVb may also be used.  
• Categorical data: number and percentage of participants  
9.3.2  Primary endpoint/estimand analysis  
See Section 3.1 for definition of primary endpoint/estimand.  
[IP_ADDRESS]  Definition of endpoint/estimands  
Plasma HIV -[ADDRESS_371672] comparisons with data 
from other compounds publicly available in the same scale, and hence aid in 
interpretation.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 84 [IP_ADDRESS]  Main Analytica l Approach  
The primary efficacy analysis will be based on the Full Analysis Set.  
Maximum change from baseline in plasma HIV -1 RNA during monotherapy will be 
summarized by [CONTACT_303839], in original and log 10 scales.  
In addition, change from baseline in plasma HIV -1 RNA at each assessment time point 
during monotherapy will be summarized by [CONTACT_303839], in original 
and log 10 scales.  
For participants who withdraw from study prior to the end of monot herapy period, 
preventing assessment of primary endpoint, no imputation will be performed for missed 
assessments after their study withdrawal.  
[IP_ADDRESS]  Supplementary/supportive analysis  
A supplementary analysis could be conducted to summarize maximum change from 
Baseline and change from baseline by [CONTACT_103718] -1 RNA during the 
monotherapy period based on the Per Protocol analysis set. Details will be provided in 
the SAP.  
9.3.3  Secondary endpoints/estimands analyses  
See Section 3.2 for definition of secondary endpoints/estimands.  
[IP_ADDRESS]  Safety analyses  
All safety analyses will be performed on the Safety analysis set. Safety data will be 
presented in tabular format and summarized descriptively according to [COMPANY_004]’s IDSL.  
The number and proportion of participants with AEs will be tabulated overall and by 
[CONTACT_86953], by [CONTACT_303839]. The number and proportion of 
participants with AEs leading to discontinuation of study intervention will also be 
tabulated by [CONTACT_15994]. In AE tabulations, each participant’s AE will be counted once 
under  the maximum severity. AEs will be tabulated using MedDRA preferred terms. AEs 
will be tabulated for the monotherapy period and overall (i.e., monotherapy period plus 
SOC period) separately.  
For liver panel laboratory parameters, summary statistics of cha nge from baseline values 
by [CONTACT_303841]. Number and percentage of 
participants with maximum toxicity grade increase from baseline for liver panel 
parameters will be presented by [CONTACT_303842] l evel; this will be done 
separately for the monotherapy period and overall (i.e., monotherapy period plus SOC).  
No imputation will be performed for missed assessments while participants are on study 
or after study withdrawal.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 85 [IP_ADDRESS]  Pharmacokinetic analyses  
All ph armacokinetic analyses will be performed on the pharmacokinetic analysis set.  
Pharmacokinetic analysis will be the responsibility of the CPMS Department at [COMPANY_004]. 
Plasma concentration -time data will be analyzed by [CONTACT_105] -compartmental methods with 
WinNonlin 8. 1 or higher, Phoenix (Pharsight Corporation) or comparable software to 
derive the PK parameters. This analysis will be based on actual sampling times recorded 
during the study. Individual plasma PK parameters for each participant will be 
determined, includ ing but not limited to Cmax and tmax.  
Data summaries of plasma concentration and pharmacokinetic parameter data will be the 
responsibility of Clinical Statistics. Plasma concentrations will be presented in graphical 
form and will be summarized descriptive ly by [CONTACT_15994]. PK parameters will be 
summarized descriptively by [CONTACT_15994].  
The data from this study will be reported in the study report. The data also may be 
combined with the data from other studies for a population PK analysis, which will be 
repor ted separately.  
No imputation will be performed for missed plasma concentrations and PK parameters 
while on study or after study withdrawal.  
[IP_ADDRESS]  Pharmacokinetic -Pharmacodynamic analyses  
Pharmacokinetic -pharmacodynamic analyses will be the responsibility of the CPMS 
Department at [COMPANY_004]. The relationship between selected PK parameters (e.g., 
concentrations on Day 10) and selected PD parameters (e.g., maximum change from 
baseline in log10 plas ma HIV -1 RNA) will be explored graphically. Where relationships 
are apparent, exposure -response models will be used to characterize the relationship and 
assess the impact of covariates. The details of such exposure -response analysis will be 
outlined in a  separate CPMS analysis plan and may be presented separately from the 
main study report . 
[IP_ADDRESS]  Virology analyses  
Genotypic assessments will be analyzed separately by [CONTACT_184880].  
[IP_ADDRESS]  Immunology analyses  
The immunology analyses will be performed using the saf ety analysis set. Change from 
baseline in CD4+ T -cell count will be summarized descriptively.  
9.3.4  Exploratory endpoints/estimands analysis  
Details on the analyses of exploratory endpoints and other analyses will be included in 
the SAP.  
CONFIDENTIAL  
 TMF-[ADDRESS_371673] completed their monotherapy period.   
The planned interim analysis will evaluate the PK and pharmacodynamic (antiviral 
activity) of VH4524184 and inform the need for P art 2, as well as future clinical 
development of VH4524184.  
Additional interim analyses may be performed during the course of the study to inform 
internal decision -making activities and/or support regulatory requests. No changes to the 
conduct of the study will be implemented as a result of these analyses.  
The final EoS analysis will  be conducted after the completion of the study (i.e., when all 
participants complete the SOC period on Day 38 visit) and final datasets authorization. At 
the EoS analysis all primary, secondary and exploratory objectives will be evaluated with 
two excepti ons: the analysis of the viral resistance and pharmacogenetics (if done) may 
be evaluated at a later stage and each of these outcomes reported separately.  
9.5 Sample size determination  
The sample size is based on feasibility and no formal calculation of power or sample size 
has been performed.  
9.5.1  Sample size considerations  
Based on viral load decline data from 2 previous POC studies investigating  [Min, 
2011; Spreen , 2013]  we assumed the maximum VLD from baseline in log10 scale for 
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 87 individual participants follows a  normal distribution. The expected precision of the 
estimated maximum VLD in log10 scale, measured by [CONTACT_941] 95% CI width, under various 
sample sizes and assumed data variability (reflected by [CONTACT_103723]) is shown in the 
table below.  
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 88 10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  
10.1 Appendix 1: Regulatory, ethical, and study oversight 
considerations  
10.1.1  Regulatory and ethical considerations  
• This study will be conducted in accordance with the protocol and with the following:  
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and CIOMS international ethical guidelines  
o Applicable ICH GCP guidelines  
o Applicabl e laws and regulations  
• The protocol, protocol amendments, ICF, IB, and other relevant documents (e.g., 
advertisements) must be submitted to an IRB/IEC by [CONTACT_97277]/IEC before the study is initiated.  
• Substantial amendments to the protocol will require IRB/IEC approval before 
implementation of changes made to the study design, except for changes necessary to 
eliminate an immediate hazard to study participants.  
• Protocols and any substantial amendments to the protoc ol will require health 
authority approval prior to initiation except for changes necessary to eliminate an 
immediate hazard to study participants.  
• The investigator will be responsible for the following, as applicable:  
o Providing written summaries of the sta tus of the study to the IRB/IEC annually 
or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC  
o Notifying the IRB/IEC of SAEs or other significant safety findings as required 
by [CONTACT_1744]/IEC procedures  
o Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable), and all other applicable local 
regulations  
10.1.2  Financial disclo sure  
Investigators and sub -investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulato ry authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 89 10.1.3  Informed consent process  
• The investigator or the investigator’s representative will explain the nature of the 
study, including the risks and benefits, to the participants and answer all questions 
regarding the study.  
• Potential participants must  be informed that their participation is voluntary. They  will 
be required to physically or digit ally sign a statement of informed consent that meets 
the requirements of 21 CFR 50, local regulations, ICH guidelines, HIPAA 
requirements, privacy and data protection requirements, where applicable, and the 
IRB/IEC or study center.  
• The medical record must include a statement that physical or digital informed consent 
was obtained before the participant was enrolled in the study and the date the physical 
or digital consent was obtained. The authorized person obtaining the informed 
consent must also sign the I CF. 
• Participants must be reconsented to the most current version of the ICF(s) during their 
participation in the study.  
• A physical or digital copy of the ICF(s) must be provided to the participant.  
• Participants who are rescreened are required to sign a new  ICF. 
The ICF will contain a separate section that addresses the use of remaining mandatory 
samples for optional exploratory research. The investigator or authorized designee will 
explain to each participant the objectives of the exploratory research. Part icipants will be 
told that they are free to refuse to participate and may withdraw their consent at any time 
and for any reason during the storage period . 
In case of unexpected pregnancy, the participant must be informed that PI [INVESTIGATOR_303795] -up. Consent for 
collection of information about the baby [CONTACT_103724]/or 
their partner as per local regulations . 
10.1.4  Recruitment strategy  
Participants will be recruited into  this study using a variety of methods, including but not 
limited to: investigators existing databases, local advertising, digital recruitment 
campaigns, and online prescreening and referral to site. Recruitment materials will be 
reviewed and approved by t he IRB/IEC before use.  
10.1.5  Data protection  
• Participants will be assigned a unique identifier by [CONTACT_093]. Any participant 
records or datasets that are transferred to the sponsor will contain the identifier only; 
participant names or any information whi ch would make the participant identifiable 
will not be transferred.  
• VH/[COMPANY_004] will ensure protection of the personal data of the investigator and site staff 
which is collected within the framework of and for the purpose of the study.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 90 • The participant must be i nformed that their personal study -related data will be used 
by [CONTACT_10999]. The level of disclosure 
must also be explained to the participant, that their data will be used as described in 
the informed consent.  
• The participant  must be informed that their medical records may be examined by 
[CONTACT_78582], by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
• The con tract between sponsor and study sites specifies responsibilities of the parties 
related data protection, including handling of data security breaches and respective 
communication and cooperation of the parties.  
• Information technology systems used to collect, process, and store study -related data 
are secured by [CONTACT_56856], alteration, or unauthorized disclosure or 
access.   
10.1.6  Committee  structure  
Participa nt safety will be routinely monitored by [CONTACT_303843](s). Pertinent findings and conclusions are shared with the product’s SRT for 
periodic review of the overall benefit risk profile of the product and escalated, as 
necess ary to VSLC.  
An SRT is in place for each VH product. It comprises of a global cross -functional 
VH/[COMPANY_004] team responsible for the ongoing assessment of benefit -risk for a product. The 
SRT contribute to the continual blinded assessment of incoming new efficacy , safety and 
PK information. An external data and safety monitoring committee is not utilized in this 
study due to the relatively small size and early phase of the trial. This is further supported 
by [CONTACT_303844] -clinical toxicity studies 
and preliminary clinical study of VH4524184.  
VSLC is a governance group that will review data and the team’s recommendation when 
any pausing/stoppi[INVESTIGATOR_26501]. The VSLC will govern whether enrollment may be 
resumed/mod ified, a given treatment arm will be stopped, or the study stopped. The 
VSLC is comprised of senior representatives from various departments, including clinical 
development, safety, toxicology, pharmacovigilance, epi[INVESTIGATOR_623], and medical affairs.  
ViiV Hea lthcare has transferred certain sponsor obligations (e.g., clinical operations, 
study intervention management, data management, statistics and programming, clinical 
pharmacology and modelling and simulation, regulatory, pharmacovigilance, etc.) to 
[COMPANY_004] who are supporting VH in the conduct of this study.  
Refer to the List of Clinical Laboratories and Key Vendors document  for the names and 
addresses for the clinical laboratories, contractors and subcontractors used by [CONTACT_103728].  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 91 10.1.7  Dissemination of Clinical Study Data  
• The key design elements of this protocol and results summaries will be posted on 
www.ClinicalTrials.gov  and/or VH Clinical Study Register in compliance with 
applicable regulations/VH policy. VH/[COMPANY_004]  will aim to register protocols summari es 
prior to study start and target results summaries submission within 12 months of 
primary/ study completion date. Where external regulations require earlier disclosure, 
VH/[COMPANY_004] will follow those timelines.  
• Where required by [CONTACT_5151], summaries will als o be posted on applicable national 
or regional clinical study registers.  
• Where required by [CONTACT_25435], an investigator signatory will 
be identified for the approval of the study report, and provided reasonable access to 
statistical tables, figures, and relevant reports. VH/[COMPANY_004] will also provide the 
investigator with the full summary of the study results, including a summary of trial 
results understandable to laypersons. The investigator is encouraged to share the plain 
language summa ry with the study participants, as appropriate. The full study report 
will be made available upon request, after decision on marketing authorization by 
[CONTACT_12721].    
• VH/[COMPANY_004] will provide the investigator with the randomization codes and particip ant-
level line listings for their site only after completion of the full statistical analysis.  
• VH/[COMPANY_004] intends to make anonymized participant -level data from this study available 
to external researchers for scientific analyses or to conduct further research  that can 
help advance medical science or improve patient care. This helps ensure the data 
provided by [CONTACT_103729].  
10.1.8  Data quality assurance  
• All participant data relating to the  study will be recorded on printed or electronic 
CRFs unless transmitted to the sponsor or designee electronically (e.g., laboratory 
data). The investigator is responsible for verifying that data entries are accurate and 
correct by [CONTACT_208572].  
• Guidance on completion of eCRFs will be provided in eCRF completion guidelines.  
• The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source docum ents. 
• QTLs will be predefined in the QTL plan to identify systematic issues that can impact 
participant right, safety and/or reliability of study results. These predefined 
parameters will be monitored during the study, and important deviations from the 
QTL s and remedial actions taken will be summarized in the CSR.  
• Monitoring details describing strategy, including definition of study critical data 
items and processes (e.g., risk -based initiatives in operations and quality such as risk 
management and mitigati on strategies and analytical risk -based monitoring, 
involvement of central reading mechanism) methods, responsibilities, and 
CONFIDENTIAL  
 TMF-17008580  
 218806  
 92 requirements, including handling of noncompliance issues and monitoring techniques 
(central, remote, or on -site monitoring) are pro vided in the monitoring plan.  
• The sponsor or designee is responsible for the data management of this study, 
including quality checking of the data.  
• The sponsor assumes accountability for actions delegated to other individuals (e.g., 
contract research organ izations).  
• Records and documents, including signed ICF, pertaining to the conduct of this study 
must be retained by [CONTACT_1732] 25 years from the issue of the final CSR/ 
equivalent summary unless local regulations or institutional policies require  a 
different retention period. No records may be destroyed during the retention period 
without the written approval of the sponsor. No records may be transferred to another 
location or party without written notification to the sponsor.  
• When copi[INVESTIGATOR_303796] a central reader 
mechanism (e.g., endpoint adjudication committee; expert reader), documents are 
stored by [CONTACT_97284] 25 years . 
10.1.9  Source documents  
• Source documents provide evidence for the existence  of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
• Data reported on the eCRF or entered in the eCRF  that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available.  
• Definition of what constitutes source data and its  origin can be found in source data 
acknowledgment or monitoring guidelines.  
• The investigator must maintain accurate documentation (source data) that supports 
the information entered in the eCRF.  
• The sponsor or designee will perform monitoring to confirm that data entered into the 
eCRF by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currentl y approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
10.1.[ADDRESS_371674] of recruitment are defined as FSFV (f irst ICF signature 
[CONTACT_568]) at a country -level.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 93 Study/Site Termination  
VH/[COMPANY_004] or designee reserves the right to close the study site or terminate the study at 
any time for any reason at the sole discretion of VH/[COMPANY_004]. Study sites will be closed upon 
study comp letion. A study site is considered closed when all required documents and 
study supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable 
cause  and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_103086]:  
For study termination:  
• Discontinuation of further study intervention de velopment  
For site termination:  
• Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor’s procedures, or GCP guidelines  
• Inadequate or no recruitment (evaluated after a reasonable amo unt of time) of 
participants by [CONTACT_093]  
• Total number of participants included earlier than expected  
If the study is prematurely terminated or temporarily suspended, the sponsor shall 
promptly inform the investigators, the IECs/IRBs, the regulatory  authorities, and any 
contract research organization(s) used in the study of the reason for termination or 
temporary suspension, as specified by [CONTACT_1214]. The 
investigator shall promptly inform the participant and should assur e appropriate 
participant therapy and/or follow -up. 
10.1.11  Publication policy  
The results of this study may be published in peer reviewed scientific literature and/or 
presented at scientific meetings. The sponsor will comply with the requirements for 
publication of study results in accordance with standard editorial and ethical practice and 
as per the sponsor’s internal policy. Authorship will be determined by [CONTACT_103730].  
  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 94 10.2 Appendix 2: Clinical laboratory tests  
• The clinical safety laboratory tests detailed in Table 9 will be performed by [CONTACT_19979].  
• Local laboratory results are only required in the event that the  central laboratory 
results are not available in time for either study intervention administration and/or 
response evaluation. If a local sample is required, it is important that the sample for 
central analysis is obtained at the same time. Additionally, i f the local laboratory 
results are used to make either a study intervention decision or response evaluation, 
the results must be recorded . 
• Protocol -specific requirements for inclusion or exclusion of participants are detailed 
in Section 5 of the protocol.  
• Additional tests may be performed at any time during the study as determined 
necessary by [CONTACT_11006].  
• Investigators must document their review of each laboratory safety report.  
Table 9 Protocol -required safety laboratory tests  
Laboratory Tests  Parameters  
Hematology  ▪ Platelet count  
▪ Red blood cell (RBC) count  
▪ RBC indices  ▪ Mean corpuscular volume (MCV)  
▪ Mean corpuscular hemoglobin (MCH)  
▪ %Reticulocytes  
▪ WBC count with 
differential:  ▪ Neutrophils  
▪ Lymphocytes  
▪ Monocytes  
▪ Eosinophils  
▪ Basophils  
▪ Hemoglobin  
▪ Hematocrit  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 95 Laboratory Tests  Parameters  
Clinical chemistry1 ▪ Blood urea nitrogen 
(BUN)/Urea  
▪ Potassium  
▪ Creatinine2 
▪ Sodium  
▪ Bicarbonate  
▪ Magnesium  
▪ Phosphate  
▪ Calcium  
▪ Glucose (fasting)  
▪ Creatine 
phosphokinase 
(CPK)5 ▪ Aspartate aminotransferase (AST)/serum glutamic -
oxaloacetic transaminase (SGOT)  
▪ Alanine aminotransferase (ALT)/serum glutamic -pyruvic 
transaminase (SGPT)  
▪ Alkaline phosphatase3 
▪ Total bilirubin  
▪ Direct bilirubin4 
▪ Total protein  
▪ Amylase  
▪ Lipase (fasting)  ▪ Fasting lipid panel (cholesterol, triglycerides, high -density 
lipoprotein [HDL], low -density lipoprotein [LDL])   
Coagulation  ▪ Prothrombin time (PT)   
▪ Partial thromboplastin time (PTT)   
International normalized ratio (INR)   
Routine urinalysis  ▪ Specific gravity  
▪ pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase by 
[CONTACT_5230]  
▪ Microscopic examination (if blood or protein is abnormal)  
▪ Epi[INVESTIGATOR_1663]  
▪ Red Blood cells  
▪ WBC  
▪ Casts  
▪ Crystals  
▪ Culture (if positive: specify pathogen)  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 96 Laboratory Tests  Parameters  
Other screening tests  ▪ Follicle stimulating hormone and estradiol (as needed in PONCBP only [See Section 
10.4.1 ] Contraceptive and barrier guidance - Definitions ) 
▪ Highly sensitive (serum or urine) human chorionic gonadotropin (hCG) pregnancy test 
participants female at birth .[See Section 1.3, Schedule of Activities]  
▪ Serum or urine alcohol, cotinine, and drug screen (to include at minimum: 
amphetamines, barbiturates, cocaine, opi[INVESTIGATOR_858], cannabinoids a nd benzodiazepi[INVESTIGATOR_1651])  
▪ Serology [(HIV antibody 4th generation test, HBsAg, and HCV antibody  Hepatitis B 
surface antibody (anti -HBs) and if indicated hepatitis B DNA (by [CONTACT_954]), and hepatitis C 
virus antibody)], with reflex to HCV RNA (by [CONTACT_954]) if positive . 
▪ Syphi lis positive rapid plasma reagin (RPR)  
NOTES:  
1. Details of liver chemistry stoppi[INVESTIGATOR_21357] -up are given in Section 7.1.2  Liver 
Chemistry Stoppi[INVESTIGATOR_303797]  10.5: Liver Safety: Suggested Actions and Follow -up Assessments. All 
events of ALT ≥3 × upper limit of normal (ULN) and total bilirubin ≥2 × ULN (>  35% direct bilirubin) or ALT  ≥3 × 
ULN and international normalized ratio (INR) >1.5 (if INR measured), which may indicate severe liver injury 
(possible Hy’s la w), must be reported to VH/[COMPANY_004] in 24 hours (excluding studies of hepatic impairment or 
cirrhosis).  
2. To assess the kidney function, use the CKD -EPI [INVESTIGATOR_10908] (2021).  
3. If alkaline phosphatase is elevated, consider fractionating.  
4. Direct bilirubin will be reflex ively performed for all total bilirubin values >1.5 × ULN  
5. Recommend repeat testing if CPK is elevated to ensure the result is transient or due to exercise. A history 
regarding use of drugs known to cause increase of CPK (such as statins), physical activity  or exercise preceding 
the CPK evaluation should be obtained.  
  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 97 10.3 Appendix 3: AEs and SAEs: Definitions and procedures for 
recording, evaluating, follow -up, and reporting  
10.3.1  Definition of AE  
AE definition  
• An AE is any untoward medical occurrence in a clinical  study participant, 
temporally associated with the use of a study intervention, whether or not 
considered related to the study intervention.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), sympto m, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.  
 
Events Meeting the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (e.g., ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (i.e., not 
related to progression of underlying disease).  
• Exacerbation of  a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New condition detected or diagnosed after study intervention administration even 
though it may have been present before the start  of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected intervention - intervention 
interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will  not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.  
• Events that occur as a result of protocol -mandated procedures (i.e. invasive 
procedures, modification of participant’s previous therapeutic regimen).  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not 
be reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the s igns, symptoms, and/or clinical sequelae resulting 
from lack of efficacy will be reported as AE or SAE if they fulfill the definition of 
an AE or SAE.   
 
CONFIDENTIAL  
 TMF-17008580  
 218806  
 98 Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or othe r abnormal safety 
assessments that are associated with the underlying disease, unless judged by [CONTACT_11009]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms  of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.  
• Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.  
• Situations in which an untoward me dical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307], admission for routine examination.).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not  worsen. Pre -existing 
diseases will be recorded in the medical history section of the eCRF.  
• Hospi[INVESTIGATOR_5187] a pre -existing condition (known or 
diagnosed before signing the informed consent) that did not worsen from baseline.  
• DRE, typi[INVESTIGATOR_303798]. These events will be 
recorded in the participant’s eCRF  and will be monitored by [CONTACT_303845] a routine 
basis. However, if 1 or both of the following conditions apply, then the event 
should be reported promptly  to VH/[COMPANY_004] as an SAE (see Section 8.4.8 ): 
• The event is, in the investigator’s opi[INVESTIGATOR_1649], of greater intensity, frequency, or 
duration than expected for the individual participant, or  
• The investigator considers that there is a reasona ble possibility that the event was 
related to the administration of the study intervention  
10.3.[ADDRESS_371675] medical occurrence that, at any dose, meets 
one or more of the criteria listed:  
a. Results in death  
b. Is life threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more s evere.  
c. Requires inpatient hospi[INVESTIGATOR_1081]  
• In general, hospi[INVESTIGATOR_12994] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_303799]/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospi[INVESTIGATOR_42244]. If a complication prolongs hospi[INVESTIGATOR_303800]-17008580  
 218806  
 99 other serious criteria, the event  is serious. When in doubt as to whether 
“hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be considered serious.  
• Hospi[INVESTIGATOR_5187] a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
d. Result s in persistent or significant disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (e.g., sprained ankle) that may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth de fect in the offspring of a study participant  
f. Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy)  
g. Is a suspected transmission of any infectious agent via an authorized medicinal 
product  
h. Other situations:  
• Possible Hy’s Law case: ALT ≥ 3x ULN AND total bilirubin ≥2x ULN (>35% 
direct bilirubin) or INR >1.[ADDRESS_371676] be reported as SAE  
• Medical or scientific judgment should be exercised by [CONTACT_303846]. These events should usually be c onsidered serious.  
o Examples of such events include invasive or malignant cancers, intensive 
treatment for allergic bronchospasm, blood dyscrasias, convulsions, or 
development of intervention dependency or intervention abuse.  
10.3.3  Unsolicited AE  
• Definition of unsolicited AE  
• An unsolicited AE is an AE that was not solicited using a participant diary and that 
is communicated by a participant who has signed the informed consent. 
Unsolicited AEs include serious and nonserious AEs.  
• Potential unsolicited AEs may be medically attended (i.e., symptoms or illnesses 
requiring a hospi[INVESTIGATOR_059], emergency room visit, or visit to/by a healthcare 
provider). The participants will be instructed to contact [CONTACT_103088](s), as well as any events that, though not 
medically attended, are of participant concern. Detailed information about reported 
unsolicited AEs will be collected by [CONTACT_103734]’s records.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 100 • Unsolicited AEs that are not medically attended nor perceived as a concern by [CONTACT_103735].  
10.3.4  Definition of CV events  
CV definition:  
Investigators will be required to fill out the specific CV event page of the eCRF for the 
following AEs and SAEs:  
• Myocardial infarction/unstable angina  
• Congestive heart failure  
• Arrhythmias  
• Valvulopathy  
• Pulmonary hypertension  
• Cerebrovascular events/stroke and transient ischemic attack  
• Peripheral arterial thromboembolism  
• Deep venous thrombosis/pulmonary embolism  
• Revascularization  
10.3.5  Definition of TEAE  
TEAE Definition:  
• A TEAE is an event that emerges during treatment, having been absent pre -
treatment or worsens relative to the pre -treatment state.  
10.3.6  Recording assessment and follow -up of AEs , SAEs and pregnancies  
[IP_ADDRESS]  AE and SAE recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics 
reports) related to the event.  
• The investigator will then record all relevant AE/SAE information.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to VH/[COMPANY_004] in lieu of completion of the [COMPANY_004] requ ired form.  
• There may be instances when copi[INVESTIGATOR_103661]/[COMPANY_004]. In this case, all participant identifiers, with the exception of 
CONFIDENTIAL  
 TMF-17008580  
 218806  
 101 the participant number, will be redacted on the copi[INVESTIGATOR_155970] e 
submission to VH/[COMPANY_004].  
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE.  
[IP_ADDRESS]  Assessment of intensity  
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to 1 of the following categories according to the DAIDS 
toxicity scales (refer to Section  10.6).  
• Where a DAIDS toxicity scale is not available for a particular event or parameter, 
then the investigator will instead make an assessment of intensity using 1 of the 
severity categories  described in the functional DAIDS table shown in Section  10.6. 
• Note:  An event is defined as ‘serious’ when it meets at least 1 of the pre -defined 
outcomes as described in the definition of an SAE.  
• Note:  Grade 4 DAIDS toxicity grades for laboratory parameters that are 
asymptomatic would not necessarily be considered SAEs, a clinical correlation 
would be necessary.  
[IP_ADDRESS]  Assessment of causality  
• The investigator is obli gated to assess the relationship between study intervention 
and each occurrence of each AE/SAE. The investigator will use clinical judgment to 
determine the relationship.  
• A reasonable possibility  of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study inte rvention 
administration, will be considered and investigated.  
• For causality assessment, the investigator will also consult the IB and/or product 
information, for marketed products.  
• The investigator must review and provide an assessment of causality for eac h 
AE/SAE and document this in the medical notes There may be situations in which an 
SAE has occurred and the investigator has minimal information to include in the 
initial report to VH/[COMPANY_004]. However, it is very important that the investigator always 
make an  assessment of causality for every event before the initial transmission of the 
SAE data to VH/[COMPANY_004].  
• The investigator may change their opi[INVESTIGATOR_9242] -up 
information and send an SAE follow -up report with the updated causality 
assessm ent. 
CONFIDENTIAL  
 TMF-17008580  
 218806  
 102 • The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
[IP_ADDRESS]  Assessment of outcomes  
The investigator will assess the outcome of all serious and nonserious unsolicited AEs 
recorded during the study as:  
• Recove red/resolved  
• Recovering/resolving  
• Not recovered/not resolved  
• Recovered with sequelae/resolved with sequelae  
• Fatal (SAEs only).  
[IP_ADDRESS]  Follow -up of AEs, SAEs  or pregnancies  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_103701]/[COMPANY_004]  
to elucidate the nature and/or causality of the AE or SAE as fully as possible. This 
may include additional laboratory tests or investigations, histopathological 
examinations,  or consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized follow -
up period, the investigator will provide VH/[COMPANY_004] with a copy of any postmortem 
findings including histopathology.  
• New or updated information will be recorded in the originally submitted documents.  
• The investigator will submit any updated SAE data to VH/[COMPANY_004] within 24 hours of 
receipt of the information.  
• After the initial AE/SAE /pregnancy  or any other event of interest, the investigator is 
required to proactively follow each participant at subsequent visits/contacts. All 
SAEs,  will be followed until the event is resolved, stabilized, otherwise explained, or 
the participant is lost to follow -up. 
Follow -up during the study  
AEs documented at a previous visit/contact [CONTACT_103736]/not resolved or 
recovering/resolving will be reviewed at subsequent visits/contacts until the end of the 
study or until  the participant is lost to follo w-up. 
If a participant dies during their participation in the study or during a recognized follow -
up period, VH/[COMPANY_004] will be provided with any available postmortem findings, including 
histopathology.  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 103 Follow -up of pregnancies  
Pregnant participants will be followed to determine the outcome of the pregnancy. At the 
end of the pregnancy, whether full -term or premature, information on the status of the 
mother and child will be forwarded to VH/[COMPANY_004] using the paper pregnancy follow -up 
report and the AE Report if a pplicable. Generally, the follow -up period does not need to 
be longer than [ADDRESS_371677] report any SAE occurring as a result of a poststudy 
pregnancy that is considered by [CONTACT_175077], to VH/[COMPANY_004] as described in the Section [IP_ADDRESS] . 
[IP_ADDRESS]  Updating of SAE  and pregnancy  information  after removal of write 
access to the participant’s eCRF  
When additional SAE or pregnancy  information is received after wri te access to the 
participant’s eCRF is removed, new or updated information should be recorded on the 
appropriate paper report, with all changes signed and dated by [CONTACT_093]. The 
updated report should be sent to the Study contact [CONTACT_103738] (refer to Section 
8.4.8 . 
[IP_ADDRESS]  Reporting of SAEs and pregnancies  
SAE Reporting to VH/[COMPANY_004] via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to VH/[COMPANY_004] will be the electronic data 
collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) to report the event within 24 hours.  
• The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
• After the study is completed at a given site, the electronic data collection tool will be 
taken offline to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SA E from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken offline, then the site can report this information on a paper SAE form (see next 
section) or to the VH medical monitor  by [CONTACT_756].  
• If the site during the course of the study or poststudy becomes aware of any serious, 
nonserious AEs, pregnancy exposure, related to any [COMPANY_004] non -IMP they will report 
these events to [COMPANY_004] or to the concerned competent authority  (CA)  via the na tional 
spontaneous reporting system.   These will be classified as spontaneous  ICSRs.  
• Contacts for SAE reporting can be found in Section 8.4.8 
CONFIDENTIAL  
 TMF-17008580  
 218806  
 104 SAE Reporting to VH/G SK via Paper Data Collection Tool  
• Email/facsimile transmission of the SAE paper data collection tool is the preferred 
method to transmit this information to the VH  medical monitor.  
• In rare circumstances and in the absence of email/facsimile equipment, notification 
by [CONTACT_9337] a copy of the SAE data collection tool sent by 
[CONTACT_22855].  
• Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE data collection to ol within the designated reporting 
timeframes.  
• Contacts for SAE reporting can be found in Section  8.4.8 . 
10.3.7  Timeframes for Reporting SAEs, PSRAEs, Pregnancy,  and Liver 
Events  
Table 10 Timeframes for Reporting SAEs, PSRAEs, Pregnancy, and Liver 
Events  
 Initia l Reports  Follow -up Information  
on a Previous Report  
Type of Event  Timeframe  Documents  Timeframe  Documents to be 
Updated  
All SAEs  24 hours  SAE eCRF a 24 hours  SAE eCRF a 
Possible 
Suicidality 
Related Adverse 
Event (SAE)  SAE eCRFa   
24 hours  SAE eCRF a SAE eCRFa   
24 hours  SAE eCRF a 
PSRAE eCRF 
and Form  
1 week  PSRAE eCRF and Form  PSRAE eCRF 
and Form  
1 week  PSRAE eCRF and Form  
Possible 
Suicidality 
Related Adverse 
Event (AE)  1 week  AE eCRF  
1 week  AE eCRF  
PSRAE eCRF and Form  PSRAE eCRF and Form  
Pregnancy  24 hours  Pregnancy Initial  
Notification Form  24 hours  Pregnancy Follow -up 
Form  
ALT 3×ULN 
and bilirubin 
2×ULN (>35% 
direct)d or 
international 
normalized ratio 
(INR) >1.5 24 hours b SAE eCRF a 
24 hours  SAE eCRF a 
Liver Event eCRF c Liver Event eCRF c 
Liver Imaging and/or 
Liver Biopsy eCRFs, if 
applicable c  Liver Imaging and/or 
Liver Biopsy eCRFs, if 
applicable c 
CONFIDENTIAL  
 TMF-17008580  
 218806  
 105 a. See Section [IP_ADDRESS]  Reporting of SAE to ViiV Healthcare/[COMPANY_004].  For each SAE, the investigator(s) must 
document in the medical notes that they have reviewed the SAE and have provided an assessment of causality. If 
the electronic system (eCRF) is unavailable, then the site will use the paper SAE data collection tool to report the 
event within 24 hours.  Paper reports will be dated and signed by [CONTACT_093] (or designee).   
b. The Medical Monitor must be contact[INVESTIGATOR_530] a t onset of liver chemistry elevations to discuss participant safety.  
c.  Liver event documents (i.e., “Liver Event eCRF” and updates, “Liver Imaging eCRF” and/or “Liver Biopsy eCRF”, 
as applicable) should be completed as soon as possible.  
d. All events of ALT≥3x ULN and bilirubin ≥2xULN (>35% direct bilirubin) or international normalized ratio (INR) >1.[ADDRESS_371678] be reported as an SAE (excluding studies of hepatic impairment or cirrhosis); INR measurement is not 
required, and the threshold value stated will not apply to participants receiving anticoagulants.  
e. Complete and submit SAE eCRF if applicable.  
  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 106 10.4 Appendix 4: Contraceptive and barrier guidance   
10.4.1  Definitions  
[IP_ADDRESS]  Participants of childbearing Potential (POCBP)  
Participants in the following categories are considered POCBP  (fertile):  
• Adolescents of childbearing potential: Tanner stage ≥2 (post -thelarche) irrespective 
of the occurrence of menarche or following menarche.  
• From the time of menarche until becoming postmenopausal unless permanently 
sterile (see below).  
Note: Menarche is the first onset of menses in a young participant assigned female at 
birth. Menarche is normally preceded by [CONTACT_103739].  
[IP_ADDRESS]  Participant of Nonchildbearing Potential (PO NCBP)  
Participants in the following categories are considered PONCBP:  
1. Premenarchal: Tanner stage 1 (prepubertal)  
2. Permanently sterile due to one of the following procedures:  
a. Documented hysterectomy  
b. Documented bilateral salpi[INVESTIGATOR_1656]  
c. Documented bilateral oop horectomy  
For permanently sterile individuals due to an alternate medical cause other than the 
above, (e.g., Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), 
investigator discretion should be applied to determining study entry. If reproduct ive 
status is questionable, additional evaluation should be considered.  
Note: Documentation can come from the site personnel’s review of the participant’s 
medical records, medical examination, or medical history interview.  
3. Postmenopausal female  
• A postmenop ausal state is defined as no menses for 12 months without an 
alternative medical cause.  
• A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of 12 months of amenorrhea, confirmation with more 
than 1 FSH measurement (>40 IU/L or mIU/mL)  is required.  
• Females on HRT and whose menopausal status is in doubt must discontinue HRT 
for at least [ADDRESS_371679] agree to use contraception/barrier as detailed 
below:  
NON -HORMONAL CONTRACEPTIVESa ALLOWED DURING THE STUDY  FOR POCBP 
INCLUDE:  
Highly Effective Methodsb That Have Low Us er Dependency  
Failure rate of <1% per year when used consistently and correctly.  
• IUD 
• Bilateral tubal occlusion  
Highly Effective Methodsb That Are User Dependent  
Failure rate of <1% per year when used consistently and correctly.  
• Sexual abstinence  
Sexual  abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of 
sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and 
usual lifestyle of the participant.  
a. Contraceptive use by [CONTACT_103092].  
b. Failure rate of <1% per year when used consistently and correctly. Typi[INVESTIGATOR_303801]: Periodic abstinence (calendar, sympto -thermal, post -ovulation methods), withdrawal (coitus interruptus),  
spermicides only, and lactational amenorrhea method (LAM) are not acceptable methods of contraception. Male 
condom and female condom should not be used together (due to risk of failure from friction)  
  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 108 10.5 Appendix 5: Liver safety: suggested actions and follow -up 
assessments  
Liver chemistry stoppi[INVESTIGATOR_303802]-absolute  
 ALT≥3xULN  
If ALT≥3xULN AND total bilirubin  ≥2xULN (>35% direct bilirubin) or 
international normalized ratio (INR) >1.5, report as an SAE1,2,3. 
Required Actions, Monitoring and Follow up Assessments  
Actions  Follow Up Assessments  
• Immediately discontinue study intervention  
• Report the event to VH medical monitor 
within 24 hours  
• Complete the liver event form and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2 
• Perform liver event follow up assessme nts 
as described in the Follow Up Assessment 
column  
• Do not restart or rechallenge participant 
with study intervention  
• Monitor the participant until liver 
chemistries resolve, stabilize, or return to 
within baseline  (see MONITORING)  
MONITORING:  
If ALT≥3xULN AND total bilirubin  2xULN 
or INR >1.5  
• Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, total bilirubin and 
INR) and perform liver event follow up 
assessments within 24 hours  
• Monitor participant twice weekly until liver 
chemi stries resolve, stabilize or return to 
within baseline  
• A specialist or hepatology consultation is 
recommended  
If ALT≥3xULN AND total bilirubin < 2xULN • Viral hepatitis serology3 
• Syphilis screening  
• Drugs of abuse screen, including alcohol  
• Obtai n INR and recheck with each liver 
chemistry assessment until the 
aminotransferases values show 
downward trend  
• Obtain blood sample for pharmacokinetic 
(PK) analysis, documenting the date and 
time of the most recent VH4524184 dose4  
• Obtain serum CPK, LDH , GGT, GLDHand 
serum albumin  
• Fractionate bilirubin, if total bilirubin 
1.5xULN  
• Obtain complete blood count with 
differential to assess eosinophilia  
• Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, fatigue, decreased 
appetite, nausea, vomiting, abdominal 
pain, jaundice, fever or rash on the liver 
event form  
• Record use of concomitant medications 
on the concomitant medications report 
form including acetaminophen, herbal 
remedies, recreational drugs, and other 
over-the-counter medications  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 109 Liver Chemistry Stoppi[INVESTIGATOR_303803] ≤1.5:  
• Perform liver chemistries (include ALT, 
AST, alkaline phosphatase, total bilirubin 
and INR)  and perform liver event follow up 
assessments within 24 -72 hours  
• Monitor participant weekly until liver 
chemistries resolve, stabilize or return to 
within baseline  • Record alcohol use on the liver event 
alcohol intake form  
If ALT≥3xULN AND total bilirubin 2xULN 
or INR >1.5 obtain the following in addition to 
the assessments listed above : 
• Anti-nuclear antibody, anti -smooth muscle 
antibody, Type 1 anti -liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG) or gamma 
globulins  
• Serum acetaminophen adduct assay 
should be done (where available) to 
assess potential acetaminophen 
contribution to liver injury unless 
acetaminophen use is very unlikely in the 
preceding week (e.g., where the 
participant has been resident in the 
clinical unit throughout). The site must 
contact [CONTACT_303847].  
• Liver imaging (ultrasound, magnetic 
resonance , or computed tomography) and 
/or liver biopsy to evaluate liver disease; 
complete Liver Imaging form and/or Liver 
Biopsy eCRF forms.  
o In participants when serology 
raises the possibility of AIH  
o In participants when suspected 
DILI progresses or fails to res olve 
on withdrawal of study 
intervention  
o In participants with acute or 
chronic atypi[INVESTIGATOR_31790].  
1. Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation testing is 
unavailable, record the absence/presence of detectable urinary bilirubin on dipstick , which is indicative of 
direct bilirubin elevations suggesting liver injury.  
2. All events of ALT ³3xULN and total bilirubin ³2xULN (>35% direct bilirubin) or ALT ³3xULN and INR >1.5, which 
may ind icate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding studies of hepatic 
impairment or cirrhosis); the INR threshold value stated will not apply to participants receiving anticoagulants  
3. Includes: hepatitis A immunoglobulin (IgM) antibody; HBsAg and HBcAb; hepatitis C RNA; cytomegalovirus IgM 
antibody; Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, heterophile antibody or monospot 
testing) and hepatitis E IgM antibody  
4. Record the date/time of the PK blood sample draw and the date/time of the last dose of study intervention prior to 
PK blood sample draw. If the date or time of the last dose is unclear, provide the participant’s best approximation. 
CONFIDENTIAL  
 TMF-17008580  
 218806  
 110 If the date/time of the last dose cannot be approximated OR a  PK sample cannot be collected in the time period 
indicated above, do not obtain a PK sample. Instructions for sample handling and shippi[INVESTIGATOR_303804]  
5. Liver biopsy may be considered and discussed with local specialists if available, for instan ce: 
• In participants when serology raises the possibility of AIH  
• In participants when suspected DILI progresses or fails to resolve on withdrawal of study intervention  
• In participants with acute or chronic atypi[INVESTIGATOR_31790].  
  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 111 10.6 Appendix 6: Division of AIDS Table for Grading the Severity of 
Adult and Pediatric Adverse Events, Corrected version 2.1, July 
2017  
VERSION 2.1, July 2017  
The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse 
Events (“DAIDS AE Grading Table”) is a descriptive terminology which can be utilized 
for Adverse Event (AE) reporting. A grading (severity) scale is provided for each AE 
term.  
• For more information, please refer to the DAIDS grading table Version 2.1, July 
2017 at (https://rsc.niaid.nih.gov/site s/default/files/daidsgradingcorrectedv21.pdf).  
10.6.1  Estimating Severity Grade for Parameters Not  Identified in the 
Grading Table 
The functional table below should be  used to g rade the severity of an AE t hat is not 
specifically identified in the  grading table. In addition, all deaths related to an AE  are to 
be classified as Grade 5 
PARA METER  GRADE 1 
MILD GRADE 2 
MODERATE      GRADE 3 
     SEVERE GRADE 4  
POTENTIALLY LIFE - 
THREATENING  
Clinical adverse 
event  NOT 
identified 
elsewhere in the 
grading table Mild symptoms 
causing no or 
minimal 
interference with 
usual social & 
functional activities 
with intervention 
not indicated Moderate symptoms 
causing greater than 
minimal interference 
with usual social & 
functional activities 
with intervention 
indicated Severe symptoms 
causing inability 
to perform usual 
social & 
functional 
activities 
with 
intervention 
or 
hospi[INVESTIGATOR_184837]-threatening 
symptoms causing 
inability to  perform basic 
self-care functions with 
intervention 
indicated to prevent 
permanent impairment, 
persistent disability, or 
death 
10.6.2  QTc prolongation using the Fridericia formula  
The DAIDS AE Grading Table provides grading for QTc prolongation using the Bazett 
formula. When the Fridericia formula is used, QTc prolongation should be graded as 
shown:  
Severity Grade 1  460 msec or greater but less than 480msec  
Severity Grade 2  480 msec or greater but less than 500 msec  
Severity Grade 3  500 msec or greater OR 60 msec or greater than baseline AND 480 msec or 
greater  
Severity Grade 4  Life-threatening consequences (e.g., Torsades de Pointes, other serious 
ventricular dysrhythmias)  
  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 112 10.7 Appendix  7 : CDC Classification for HIV -1 Infection  
Note that the CD4+ T -lymphocyte count takes precedence over the CD4+ T -lymphocyte 
percentage in HIV infection stages 1, 2, and 3.  The CD4+ T -lymphocyte percentage 
should only be considered if the count is missing.  
HIV infection, stage [ADDRESS_371680] result 
within 180 days of a positive  result.  The criteria for stage 0 supersede and are 
independent of criteria used for other stages.  
HIV infection, stage 1  
Laboratory confirmation of HIV infection with no AIDS -defining condition, and  
• CD4+ T -lymphocyte count of ≥500 cells/ L, or  
• CD4+ T -lymphocyte percentage of total lymphocytes of ≥26%.  
HIV infection, stage 2  
Laboratory confirmation of HIV infection with no AIDS -defining condition, and  
• CD4+ T -lymphocyte count of 200 to 499 cells/ L, or  
• CD4+ T -lymphocyte percentage of total lymphocytes of 14 % to 25%.  
HIV infection, stage 3 (AIDS)  
Laboratory confirmation of HIV infection, and  
• CD4+ T -lymphocyte count of <200 cells/ L, or  
• CD4+ T -lymphocyte percentage of total lymphocytes of <14%, or  
• Documentation of an AIDS -defining condition (see below).  
Docume ntation of an AIDS -defining condition supersedes a CD4+ T -lymphocyte count 
of >200 cells/ L and a CD4+ T -lymphocyte percentage of total lymphocytes of >14%.  
HIV infection, stage unknown  
Laboratory confirmation of HIV infection, and  
• No information on CD4+ T-lymphocyte count or percentage, and  
• No information on presence of AIDS -defining conditions.  
Stage -3-defining opportunistic illnesses in HIV infection  
• Candidiasis of bronchi, trachea, or lungs  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 113 • Candidiasis of esophagus  
• Cervical cancer, invasive  
• Coccidioidomycosis, disseminated or extrapulmonary  
• Cryptococcosis, extrapulmonary  
• Cryptosporidiosis, chronic intestinal (>1 month's duration)  
• Cytomegalovirus disease (other than liver, spleen, or nodes), onset at age >1 month  
• Cytomegalovirus retinitis (w ith loss of vision)  
• Encephalopathy, HIV -related  
• Herpes simplex: chronic ulcers (>1 month's duration) or bronchitis, pneumonitis, or 
esophagitis (onset at age >1 month)  
• Histoplasmosis, disseminated or extrapulmonary  
• Isosporiasis, chronic intestinal (>1 mo nth's duration)  
• Kaposi's sarcoma  
• Lymphoma, Burkitt's (or equivalent term)  
• Lymphoma, immunoblastic (or equivalent term)  
• Lymphoma, primary, of brain  
• Mycobacterium avium complex or Mycobacterium kansasii, disseminated or 
extrapulmonary  
• Mycobacterium tub erculosis of any site, pulmonary, disseminated or extrapulmonary  
• Mycobacterium, other species or unidentified species, disseminated or 
extrapulmonary  
• Pneumocystis jirovecii pneumonia  
• Pneumonia, recurrent  
• Progressive multifocal leukoencephalopathy  
• Salmon ella septicemia, recurrent  
• Toxoplasmosis of brain, onset at age >1 month  
• Wasting syndrome attributed to HIV.  
Source: [ CDC , 2014]  
CONFIDENTIAL  
 TMF-17008580  
 218806  
 114 11 REFERENCES  
CDC Revised Surveillance Case Definition for HIV Infection – [LOCATION_002], 2014. 
MMWR 2014; 63 (RR -03);[ADDRESS_371681]. 2017 May 1;75(1):61 -66. doi: 
10.1097/QAI.0000000000001306. PMID: 28196003; PMCID: PMC5389589.  
[COMPANY_004] Document Number RPS -CLIN -033920: VH4524184 Investigator’s Brochure 
Version 00 19/AUG UST /2022  
[COMPANY_004] Document Number RPS -CLIN -069016 : VH4524184 Investigator’ s Brochure 
Version 0 1 25/SEPTEMBER /2023 
[COMPANY_004] Document Number TMF -16041100 : 218803: A Phase 1 Double -Blind (sponsor -
unblinded), Placebo -Controlled Randomized, Single and Multiple Ascending Dose First -
Time -in-Human Study to Investigate the Safety, Tolerabilit y, and Pharmacokinetics of 
VH4524184 and the Potential for Changes in Cytochrome P450 3A (CYP3A) Activity. 
2023.  
Posner K, Oquendo MA, Gould M, et al. Columbia Classification Algorithm of Suicide 
Assessment (C -CASA): classification of suicidal events in the FDA’s pediatric suicidal 
risk analysis of antidepressants. Am J Psychiatry. 2007;164:1035 -1043. 
CCI
CCI
CCI
CONFIDENTIAL  
 TMF-17008580  
 218806  
 115 UNAIDS [Internet] Global AIDS Epi[INVESTIGATOR_103671] 2021 [cited on [ADDRESS_371682] 2021]. Available from  https:// Global HIV & AIDS statistics — Fact sheet | 
UNAIDS  accessed [ADDRESS_371683]  2023  
 
CCI
Signature [CONTACT_1219]  218806 TMF-17008580 v1.0
Signature [CONTACT_1220]-17008580 v1.0Reason for signing: Approved Name:
[CONTACT_1221]: Approver
Date of signature: 29-Sep-2023 14:54:28 GMT[PHONE_006]
[COMPANY_003]